Keratoconjunctivitis Sicca
Conditions
Keywords
Dry Eye Disease
Brief summary
This study is being conducted to investigate the safety, comfort, and tolerability of 3 treatments: loteprednol etabonate ophthalmic (Lotemax®) gel 0.5 percent (%) administered twice daily (BID) with or without cyclosporine ophthalmic emulsion (Restasis) 0.05% administered BID, and Restasis 0.05% treatment alone for 12 weeks and at a follow-up safety visit 1 week post-treatment. This study will also investigate the relative efficacy of Lotemax gel 0.5% administered BID with or without Restasis 0.05% treatment administered BID and of Restasis 0.05% treatment alone for the reduction of clinical signs or symptoms of keratoconjunctivitis sicca (DED) over the first 4 weeks of a 12-week treatment period and at the end of a 12-week treatment period.
Interventions
Sponsors
Synteract, Inc.
Bausch & Lomb Incorporated
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Investigator)
Eligibility
Sex/Gender
ALL
Age
40 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Have been diagnosed with or treated for keratoconjunctivitis sicca (DED) within 6 months prior to screening visit (Day -14). * Have a baseline intraocular pressure (IOP) measurement of greater than or equal to (≥) 5 millimeters of mercury (mmHg) and less than or equal to (≤) 22 mmHg in each eye, with or without anti-glaucoma therapy. * Have mild to moderate DED in 1 eye or both eyes at screening visit (Day -14) and randomization visit (Day 0).
Exclusion criteria
* Have a known hypersensitivity to corticosteroids, cyclosporine, fluorescein, lissamine green, topical anesthetic, or any component of either of the study drugs. * Have severe DED. * Have corneal erosive disease or other conditions suggestive of extensive damage of the cornea. * Have a history of elevated IOP, a history of glaucoma, or IOP greater than (\>) 22 mmHg in either eye at the screening visit (Day -14). * Have had penetrating intraocular surgery in the past 12 months or require penetrating intraocular surgery during the study. * Have had eyelid surgery within the 6 months prior to Visit 1 (Day -14) or have DED secondary to surgery. * Have visible evidence of anterior lid Demodex spp. infection or infestation. * Have had corneal refractive surgery or corneal transplantation. * Have congenitally absent lacrimal or meibomian glands or have any obstructive disease of the lacrimal glands, sarcoidosis, or any other lacrimal gland deficiency. * Have a diagnosis of on-going ocular infection, active anterior blepharitis, moderate to severe pinguecula, Stevens-Johnson syndrome, ocular cicatricial pemphigoid, significant conjunctival scarring, ocular chemical burn, or ocular neurotrophic keratitis. * Have any serious systemic disease or uncontrolled medical condition that in the judgment of the investigator could confound study assessments or limit compliance. * Have a history of ocular herpetic keratitis or have had active blepharitis in the 4 weeks prior to the first dose. * Have had ocular surgery (including laser) within 6 months prior to the first Treatment Period, or plan or require ocular surgery during the study. Neodymiumdoped:yttrium aluminum garnet (Nd:YAG) laser posterior capsulotomy is allowed.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change From Baseline in Corneal Total Fluorescein Staining Score at for the Study Eye at Week 4 | Baseline (Day 0), Week 4 | Fluorescein Corneal Staining indicates the damage to the corneal epithelium (corneal epitheliopathy). Punctate corneal staining with fluorescein was evaluated and graded according to the National Eye Institute (NEI) grading method. The cornea was divided into 5 regions: central, superior, inferior, nasal and temporal. Each of these 5 regions was graded from scores 0 to 3, where 0 indicated no staining (absent) and 3 maximal staining (severe damage). The total score was the sum of all these regions, ranged from 0 (absence of corneal epitheliopathy) to 15 (severe corneal epitheliopathy). |
| Change From Baseline in Mean Ocular Surface Disease Index (OSDI) Questionnaire Total Score at Week 4 | Baseline, Week 4 | OSDI is a 12-item questionnaire developed to assess severity of DED. There are 3 question types: Have you experienced any of following (light sensitivity, eye feel gritty, sore eyes, blurred vision, and poor vision) during last week?(items 1-5); Have problems with your eyes limited you in performing any of following (reading, driving at night, working with computer, and watching TV) during last week? (items 6-9); and Have your eyes felt uncomfortable in any of following situations (windy, low humidity, air conditioned) during the last week? (items 10-12). Response of each of these questions were graded on a scale (that relate to the frequency of ocular surface disease effects) of 0 (none of the time) to 4 (all of the time).Total OSDI score was calculated using following formula: OSDI=(\[sum of scores for all questions answered\] × 100)/(\[total number of questions answered\] \* 4). Total OSDI score ranged from 0 to 100, with higher scores representing greater disability. |
| Percentage of Participants With Adverse Events (AEs) | Baseline up to Week 13 | An AE was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Serious AEs were defined as death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized participant and required medical intervention to prevent 1 of the outcomes listed in this definition. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section. |
| Mean Grade for Participant-Reported Post-Dosing Ocular Comfort Values | Week 12 | Participants scored their degree of comfort with their assigned study drug on a 4-point scale (0-3 units) within 5 minutes after instillation of study drug. Comfort grade 0 indicated comfortable, discomfort absent; 1 indicated generally comfortable, mild discomfort; 2 indicated some discomfort but tolerable, moderate discomfort; 3 indicated severely uncomfortable or intolerable. The mean global ocular comfort grade was reported. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change From Baseline in Mean Tear Osmolarity of Participant Worst Eye Value at Week 12 | Baseline, Week 12 | Tear osmolarity was measured with the TearLab Osmolarity System. The TearLab instrument measures the impedance of 50 nanoliters (nL) tear samples taken with a disposable lab-on-a-chip device. Tear samples from enrolled participants were taken at Weeks 2, 4, and 12 from each eye in duplicate with a tear sampler according to the manufacturer's instructions, and the tear osmolarity for each sample was read with the TearLab instrument. Osmolarity values were provided by the TearLab instrument in 3-digit units of milliosmoles (mOsm). Change from mean baseline values for all participants within a treatment group was calculated using a participant's worst eye value at Week 12. |
| Change From Baseline in Mean Tear Osmolarity Between Two Eyes of Participant at Week 12 | Baseline, Week 12 | Tear osmolarity was measured with the TearLab Osmolarity System. The TearLab instrument measures the impedance of 50 nL tear samples taken with a disposable lab-on-a-chip device. Tear samples from enrolled participants were taken at Weeks 2, 4, and 12 from each eye in duplicate with a tear sampler according to the manufacturer's instructions, and the tear osmolarity for each sample was read with the TearLab instrument. Osmolarity values were provided by the TearLab instrument in 3-digit units of mOsm. Change from mean baseline values for all participants within a treatment group was calculated for the difference between average values between 2 eyes at Week 12. |
| Change From Baseline in Mean Eye Comfort Index Questionnaire Total Score and Individual Question Scores at Week 12 | Baseline, Week 12 | An ocular comfort assessment questionnaire was administered at weeks 2, 4, and 12 to participants. The assessment of the degree of dry eye discomfort experienced by the participant was conducted using an adapted and validated 12-item ocular comfort questionnaire ( to measure the frequency and intensity of 6 common dry eye symptoms: dryness, grittiness, stinging, eye tiredness, pain, and itching) based upon the ocular comfort index of Johnson and Murphy. Each item (question) was graded from 0 to 4, where 0 = Not at all, 1 = Seldom; perceptible but not intense, 2 = Sometimes; intermittent with easily tolerable intensity, 3 = Frequently; often but with tolerable intensity, 4 = Constantly; constant or intolerable intensity. Total score was calculated and normalized to a score of 0 (no discomfort)-100 (more ocular discomfort) by the formula: Normalized comfort grade = (\[Total Comfort Grade\] \* 100)/48. |
| Change From Baseline in Mean Eye Dryness Questionnaire Total and Individual Question Scores at Week 12 | Baseline, Week 12 | The 5-item Dry Eye Questionnaire (DEQ-5) is a validated questionnaire for discriminating self-assessed severity of dry eye diagnoses. The participants rated the frequency on a scale of 0 (never) to 4 (constant) with which they have experienced 3 symptoms (watery eyes, discomfort and dryness). The participant was also asked to rate the increase in intensity of discomfort and dryness throughout the day on a scale of 0 (never have it) to 5 (very intense). Participant rated the overall severity of dry eye symptoms on a scale of 0 (no problem) to 4 (intolerable; unable to perform my daily tasks). Total DEQ-5 score was the sum of scores for frequency and intensity of dryness and discomfort plus frequency of watery eyes. A DEQ-5 total score \>6 was indicative of DED and a score \>12 is indicative of Sjögren's syndrome. |
| Change From Baseline in Mean Tear Film Breakup Time (TFBUT) (by Fluorescein Staining) of the Study Eye and Averaged for Both Eyes of a Participant at Week 12 | Baseline, Week 12 | The TFBUT was defined as the interval between the last complete blink and the first appearance of dark zones or spots, or disruption in the tear film. Tear film breakup time is a measure of the stability of the tear film protecting the cornea and bulbar conjunctiva. 5 microliters (μL) of fluorescein solution was instilled in the participant's eye, after which the participant blinked several times, then kept the eye open. The cornea was visualized through the slit lamp using appropriate barrier filters for the white light source. TFBUT was counted using a stopwatch. Three consecutive measurements were taken and averaged for actual TFBUT. TFBUT at Baseline (Day 0) was subtracted from TFBUT at Week 12 (Day 84) and reported as change. A higher number represented a lengthening in the TFBUT. A longer TFBUT indicated a more stable tear film. |
| Change From Baseline in Mean OSDI Questionnaire Total Score and Individual Question Scores at Week 12 | Baseline, Week 12 | OSDI is a 12-item questionnaire developed to assess severity of DED. There are 3 question types: Have you experienced any of following (light sensitivity, eye feel gritty, sore eyes, blurred vision, and poor vision) during last week?(items 1-5); Have problems with your eyes limited you in performing any of following (reading, driving at night, working with computer, and watching TV) during last week? (items 6-9); and Have your eyes felt uncomfortable in any of following situations (windy, low humidity, air conditioned) during the last week? (items 10-12). Response of each of these questions were graded on a scale (that relate to the frequency of ocular surface disease effects) of 0 (none of the time) to 4 (all of the time).Total OSDI score was calculated using following formula: OSDI=(\[sum of scores for all questions answered\] × 100)/(\[total number of questions answered\] \* 4). Total OSDI score ranged from 0 to 100, with higher scores representing greater disability. |
| Change From Baseline in Mean Anesthetized Schirmer's Test Values (Distance of Strips Wetting) in the Study Eye and Averaged for Both Eyes of a Participant at Week 13 | Baseline, Week 13 | Schirmer's test measures the aqueous component of tear secretion. The Schirmer's test (anesthetized) is a measure of the tonic secretion of the aqueous component of tears. A Schirmer's test (with anaesthesia) was performed for both eyes of a participant using Schirmer's test strips. After instillation of an ophthalmic anaesthetic, Schirmer's test strips for each eye were left in place for 5 minutes with participant eyelids closed. After 5 minutes, the Schirmer's test strips were removed with forceps and the distance to where each strip was wetted was recorded in millimeters (mm). Lesser wetting of strips (low levels of tear production) were associated with dry eye. |
| Averaged Daily Soothe Lubricant Eye Drops Usage | Baseline up to Week 12 | Amount of averaged daily soothe lubricant eye drops (Bausch + Lomb) used was reported. |
| Number of Participants With Overall Change From Baseline in Dry Symptoms at Week 12 as Assessed Independently by Investigators and Participants | Baseline, Week 12 | Participants and investigators independently rated the overall change from baseline in dry eye conditions for each participant on a 7-point Likert scale at Week 12. The scale ranged from +3 to -3, where +3 = Substantial improvement in dry eye; little or no awareness of dry eye, +2 = Some improvement in dry eye, +1 = Little improvement in dry eye, 0 = No improvement in dry eye, -1 = Slight worsening of dry eye, -2 = Some worsening of dry eye, and -3 = Substantial worsening of dry eye. |
| Change From Baseline in Ocular Redness Score for Study Eye and Averaged for Both Eyes at Week 12, as Assessed by Investigator | Baseline, Week 12 | The Investigator subjectively rated the degree of eye redness on a 4-point (0-3) grading scale prior to any objective grading of eye redness for a participant, where score 0 = none absent; no redness present in the white of the eyes, 1 = mild, slightly dilated blood vessels seen in some portion of the white of the eyes; the color of vessels was typically pink, 2 = moderate more apparent dilation of blood vessels in the white of the eyes; vessel color was more intense (redder) and involves the majority of the vessel bed, 3 = severe numerous obvious dilated blood vessels throughout the white of the eyes; the vessel color was deep red. |
| Change From Baseline in Non-Invasive Keratographic Limbal and Bulbar Ocular Redness Scores for Study Eye and Averaged for Both Eyes at Week 12, as Assessed by Investigator | Baseline, Week 12 | The objective redness scoring assessment was conducted by automated means using an Oculus Keratograph 5M. Duplicate digital photographs of bulbar and limbal conjunctiva were taken with the Oculus Keratograph 5M instrument for each eye of a participant and the images were analyzed using R-Scan classification software to numerically rate the severity of ocular redness (bulbar and limbal redness) on a 4-point (0-3) grading scale, where score 0 = none absent; no redness present in the white of the eyes, 1 = mild, slightly dilated blood vessels seen in some portion of white of the eyes; color of vessels was typically pink, 2 = moderate more apparent dilation of blood vessels in the white of the eyes; vessel color was more intense (redder) and involves the majority of the vessel bed, 3 = severe numerous obvious dilated blood vessels throughout the white of the eyes; the vessel color was deep red. Keratograph 5M ocular redness grading results were averaged for each eye and for both eyes. |
| Change From Baseline in Mean Non-Invasive Keratographic Tear Film Breakup Time (NIKBUT) of the Study Eye and Averaged for Both Eyes of a Participant at Week 12 | Baseline, Week 12 | The tear film breakup time was defined as the interval between the last complete blink and the first appearance of dark zones or spots, or disruption in the tear film. Tear film examination using any non-invasive method analyzes optical reflections from the cornea. Reflections that become distorted are characteristic of tear film breakup. Circular images were projected onto the corneal surface using an Oculus Keratograph 5M instrument, and the tear film reflection was observed on a computer. NIKBUT (initial break-up time \[NIKBUTi\] and average break-up time \[NIKBUTav\]) were determined and recorded for each eye in duplicate after participant blink 2 times. NIKBUT at Baseline (Day 0) was subtracted from NIKBUT at Week 12 (Day 84) and reported as change. A higher number represented a lengthening in the NIKBUT. A longer NIKBUT indicated a more stable tear film. |
| Change From Baseline in Mean Corneal Total Fluorescein Staining Score for the Study Eye and Averaged for Both Eyes at Week 12 | Baseline, Week 12 | Fluorescein Corneal Staining indicates the damage to the corneal epithelium (corneal epitheliopathy). Punctate corneal staining with fluorescein was evaluated and graded according to the NEI grading method. The cornea was divided into 5 regions: central, superior, inferior, nasal and temporal. Each of these 5 regions was graded from scores 0 to 3, where 0 indicated no staining (absent) and 3 maximal staining (severe damage). The total score was the sum of all these regions, ranged from 0 (absence of corneal epitheliopathy) to 15 (severe corneal epitheliopathy). |
| Change From Baseline in Mean Value of Participant Worst Eye Score for Each Symptom (Including the Pre-Specified Worst Symptom) in the List of Possible Worst Symptoms at Week 12 | Baseline, Week 12 | Participants eligible for enrollment rated the severity of dry eye symptoms at Baseline (Day 0) on a 5-point grading scale (ranged from 0 \[no problem\] to 4 \[continuous or severe discomfort; intolerable\]) for each of 8 symptoms in the following symptom list prior to enrollment and then selected their most bothersome symptom: Photophobia, itchiness or scratchiness, grittiness or sandiness, foreign body sensation, haziness or blurriness, eye discomfort, burning or stinging, or photopsia (sensation of light or light flashes). Participants subsequently rated their dry eye symptom severity on the same 5-point grading scale at Week 2-Week 12 for study eye for the worst symptom identified at Baseline. |
| Change From Baseline in Mean Total Combined Lissamine Green (LG) Staining (Nasal Plus Temporal Conjunctival) Score for the Study Eye and Averaged for Both Eyes at Week 12 | Baseline, Week 12 | LG staining is useful for monitoring evidence of eye dryness in conjunctival tissue. Scoring of conjunctival staining was done using Oxford conjunctival grading scale. The investigator instilled an ophthalmic dye (LG stain) on the eye and rated staining in 2 areas (nasal and temporal conjunctiva). Staining was rated on a 6-point scale from 0 (absent) to 5 (severe). The total score ranged from 0 (improvement; no conjunctival damage) to 12 (worsening; severe conjunctival damage). |
Countries
United States
Participant flow
Pre-assignment details
A total of 102 participants were randomized in 1:1:1 to lotemax gel 0.5% and restasis 0.05%, lotemax gel 0.5%, or restasis 0.05% treatment groups.
Participants by arm
| Arm | Count |
|---|---|
| Lotemax Gel 0.5% and Restasis 0.05% Participants administered lotemax gel 0.5% BID OU for 2 weeks, then administered both lotemax gel 0.5% and restasis emulsion 0.05% BID OU for 2 weeks, then administered restasis emulsion 0.05% BID OU for 8 weeks. Participants also received preservative-free Soothe Lubricant Eye Drops as needed (up to 4 times per day). | 33 |
| Lotemax Gel 0.5% Participants administered lotemax gel 0.5% BID OU for 12 weeks. Participants also received preservative-free Soothe Lubricant Eye Drops as needed (up to 4 times per day). | 36 |
| Restasis 0.05% Participants administered restasis emulsion 0.05% BID OU for 12 weeks. Participants also received preservative-free Soothe Lubricant Eye Drops as needed (up to 4 times per day). | 33 |
| Total | 102 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 |
|---|---|---|---|---|
| Overall Study | Participant revealed masked treatment | 1 | 0 | 0 |
| Overall Study | Randomized but exclusion criteria met | 1 | 0 | 0 |
| Overall Study | Withdrawal by Subject | 0 | 1 | 0 |
Baseline characteristics
| Characteristic | Lotemax Gel 0.5% | Restasis 0.05% | Lotemax Gel 0.5% and Restasis 0.05% | Total |
|---|---|---|---|---|
| Age, Continuous | 64.3 years STANDARD_DEVIATION 9.1 | 61.6 years STANDARD_DEVIATION 9.98 | 62.0 years STANDARD_DEVIATION 8.3 | 62.7 years STANDARD_DEVIATION 9.14 |
| Sex: Female, Male Female | 30 Participants | 26 Participants | 25 Participants | 81 Participants |
| Sex: Female, Male Male | 6 Participants | 7 Participants | 8 Participants | 21 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — | — / — |
| other Total, other adverse events | 5 / 33 | 2 / 36 | 3 / 33 |
| serious Total, serious adverse events | 0 / 33 | 0 / 36 | 0 / 33 |
Outcome results
Primary
Change From Baseline in Corneal Total Fluorescein Staining Score at for the Study Eye at Week 4
Fluorescein Corneal Staining indicates the damage to the corneal epithelium (corneal epitheliopathy). Punctate corneal staining with fluorescein was evaluated and graded according to the National Eye Institute (NEI) grading method. The cornea was divided into 5 regions: central, superior, inferior, nasal and temporal. Each of these 5 regions was graded from scores 0 to 3, where 0 indicated no staining (absent) and 3 maximal staining (severe damage). The total score was the sum of all these regions, ranged from 0 (absence of corneal epitheliopathy) to 15 (severe corneal epitheliopathy).
Time frame: Baseline (Day 0), Week 4
Population: ITT population included all randomized participants. Missing data was imputed using mixed-effect model for repeated measures (MMRM) method. Here, 'Overall number of participants analyzed' signifies participants evaluable for this outcome measure.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Lotemax Gel 0.5% and Restasis 0.05% | Change From Baseline in Corneal Total Fluorescein Staining Score at for the Study Eye at Week 4 | -1.3 units on a scale | Standard Deviation 1.95 |
| Lotemax Gel 0.5% | Change From Baseline in Corneal Total Fluorescein Staining Score at for the Study Eye at Week 4 | -1.7 units on a scale | Standard Deviation 2.89 |
| Restasis 0.05% | Change From Baseline in Corneal Total Fluorescein Staining Score at for the Study Eye at Week 4 | -1.3 units on a scale | Standard Deviation 1.63 |
Comparison: Analysis was performed using MMRM method.p-value: 0.619995% CI: [-0.7, 1.3]Mixed Models Analysis
Comparison: Analysis was performed using MMRM method.p-value: 0.80795% CI: [-0.9, 1.2]Mixed Models Analysis
Comparison: Analysis was performed using MMRM method.p-value: 0.806895% CI: [-1.1, 0.9]Mixed Models Analysis
Primary
Change From Baseline in Mean Ocular Surface Disease Index (OSDI) Questionnaire Total Score at Week 4
OSDI is a 12-item questionnaire developed to assess severity of DED. There are 3 question types: Have you experienced any of following (light sensitivity, eye feel gritty, sore eyes, blurred vision, and poor vision) during last week?(items 1-5); Have problems with your eyes limited you in performing any of following (reading, driving at night, working with computer, and watching TV) during last week? (items 6-9); and Have your eyes felt uncomfortable in any of following situations (windy, low humidity, air conditioned) during the last week? (items 10-12). Response of each of these questions were graded on a scale (that relate to the frequency of ocular surface disease effects) of 0 (none of the time) to 4 (all of the time).Total OSDI score was calculated using following formula: OSDI=(\[sum of scores for all questions answered\] × 100)/(\[total number of questions answered\] \* 4). Total OSDI score ranged from 0 to 100, with higher scores representing greater disability.
Time frame: Baseline, Week 4
Population: ITT population included all randomized participants. Missing data was imputed using MMRM method. Here, 'Overall number of participants analyzed' signifies participants evaluable for this outcome measure.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Lotemax Gel 0.5% and Restasis 0.05% | Change From Baseline in Mean Ocular Surface Disease Index (OSDI) Questionnaire Total Score at Week 4 | -5.2 units on a scale | Standard Deviation 12.84 |
| Lotemax Gel 0.5% | Change From Baseline in Mean Ocular Surface Disease Index (OSDI) Questionnaire Total Score at Week 4 | -1.3 units on a scale | Standard Deviation 17.04 |
| Restasis 0.05% | Change From Baseline in Mean Ocular Surface Disease Index (OSDI) Questionnaire Total Score at Week 4 | -0.6 units on a scale | Standard Deviation 14.09 |
Comparison: Analysis was performed using MMRM method.p-value: 0.229695% CI: [-11.6, 2.8]Mixed Models Analysis
Comparison: Analysis was performed using MMRM method.p-value: 0.18995% CI: [-12.3, 2.5]Mixed Models Analysis
Comparison: Analysis was performed using MMRM method.p-value: 0.883695% CI: [-7.7, 6.7]Mixed Models Analysis
Primary
Mean Grade for Participant-Reported Post-Dosing Ocular Comfort Values
Participants scored their degree of comfort with their assigned study drug on a 4-point scale (0-3 units) within 5 minutes after instillation of study drug. Comfort grade 0 indicated comfortable, discomfort absent; 1 indicated generally comfortable, mild discomfort; 2 indicated some discomfort but tolerable, moderate discomfort; 3 indicated severely uncomfortable or intolerable. The mean global ocular comfort grade was reported.
Time frame: Week 12
Population: Safety population included all randomized participants who received at least 1 dose of study drug. Here, 'Overall number of participants analyzed' signifies participants evaluable for this outcome measure.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Lotemax Gel 0.5% and Restasis 0.05% | Mean Grade for Participant-Reported Post-Dosing Ocular Comfort Values | 0.5 units on a scale | Standard Deviation 0.63 |
| Lotemax Gel 0.5% | Mean Grade for Participant-Reported Post-Dosing Ocular Comfort Values | 0.6 units on a scale | Standard Deviation 0.92 |
| Restasis 0.05% | Mean Grade for Participant-Reported Post-Dosing Ocular Comfort Values | 0.5 units on a scale | Standard Deviation 0.87 |
Primary
Percentage of Participants With Adverse Events (AEs)
An AE was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Serious AEs were defined as death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized participant and required medical intervention to prevent 1 of the outcomes listed in this definition. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.
Time frame: Baseline up to Week 13
Population: Safety population included all randomized participants who received at least 1 dose of study drug.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Lotemax Gel 0.5% and Restasis 0.05% | Percentage of Participants With Adverse Events (AEs) | 27.3 percentage of participants |
| Lotemax Gel 0.5% | Percentage of Participants With Adverse Events (AEs) | 25.0 percentage of participants |
| Restasis 0.05% | Percentage of Participants With Adverse Events (AEs) | 27.3 percentage of participants |
Secondary
Averaged Daily Soothe Lubricant Eye Drops Usage
Amount of averaged daily soothe lubricant eye drops (Bausch + Lomb) used was reported.
Time frame: Baseline up to Week 12
Population: ITT population included all randomized participants.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Lotemax Gel 0.5% and Restasis 0.05% | Averaged Daily Soothe Lubricant Eye Drops Usage | 2.07 drops/day | Standard Deviation 1.013 |
| Lotemax Gel 0.5% | Averaged Daily Soothe Lubricant Eye Drops Usage | 1.79 drops/day | Standard Deviation 1.073 |
| Restasis 0.05% | Averaged Daily Soothe Lubricant Eye Drops Usage | 2.04 drops/day | Standard Deviation 1.075 |
Secondary
Change From Baseline in Mean Anesthetized Schirmer's Test Values (Distance of Strips Wetting) in the Study Eye and Averaged for Both Eyes of a Participant at Week 13
Schirmer's test measures the aqueous component of tear secretion. The Schirmer's test (anesthetized) is a measure of the tonic secretion of the aqueous component of tears. A Schirmer's test (with anaesthesia) was performed for both eyes of a participant using Schirmer's test strips. After instillation of an ophthalmic anaesthetic, Schirmer's test strips for each eye were left in place for 5 minutes with participant eyelids closed. After 5 minutes, the Schirmer's test strips were removed with forceps and the distance to where each strip was wetted was recorded in millimeters (mm). Lesser wetting of strips (low levels of tear production) were associated with dry eye.
Time frame: Baseline, Week 13
Population: ITT population included all randomized participants. Here, 'Number analyzed' signifies participants evaluable for specified categories.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Lotemax Gel 0.5% and Restasis 0.05% | Change From Baseline in Mean Anesthetized Schirmer's Test Values (Distance of Strips Wetting) in the Study Eye and Averaged for Both Eyes of a Participant at Week 13 | Wetting distance for Study eye: Baseline | 6.1 mm | Standard Deviation 1.89 |
| Lotemax Gel 0.5% and Restasis 0.05% | Change From Baseline in Mean Anesthetized Schirmer's Test Values (Distance of Strips Wetting) in the Study Eye and Averaged for Both Eyes of a Participant at Week 13 | Wetting distance for Study eye: Change at Week 13 | 2.5 mm | Standard Deviation 6.16 |
| Lotemax Gel 0.5% and Restasis 0.05% | Change From Baseline in Mean Anesthetized Schirmer's Test Values (Distance of Strips Wetting) in the Study Eye and Averaged for Both Eyes of a Participant at Week 13 | Wetting distance for both eyes: Baseline | 6.66 mm | Standard Deviation 1.76 |
| Lotemax Gel 0.5% and Restasis 0.05% | Change From Baseline in Mean Anesthetized Schirmer's Test Values (Distance of Strips Wetting) in the Study Eye and Averaged for Both Eyes of a Participant at Week 13 | Wetting distance for both eyes: Change at Week 13 | 2.17 mm | Standard Deviation 5.72 |
| Lotemax Gel 0.5% | Change From Baseline in Mean Anesthetized Schirmer's Test Values (Distance of Strips Wetting) in the Study Eye and Averaged for Both Eyes of a Participant at Week 13 | Wetting distance for both eyes: Change at Week 13 | 1.39 mm | Standard Deviation 5.61 |
| Lotemax Gel 0.5% | Change From Baseline in Mean Anesthetized Schirmer's Test Values (Distance of Strips Wetting) in the Study Eye and Averaged for Both Eyes of a Participant at Week 13 | Wetting distance for Study eye: Baseline | 6.6 mm | Standard Deviation 2.18 |
| Lotemax Gel 0.5% | Change From Baseline in Mean Anesthetized Schirmer's Test Values (Distance of Strips Wetting) in the Study Eye and Averaged for Both Eyes of a Participant at Week 13 | Wetting distance for both eyes: Baseline | 6.78 mm | Standard Deviation 2.01 |
| Lotemax Gel 0.5% | Change From Baseline in Mean Anesthetized Schirmer's Test Values (Distance of Strips Wetting) in the Study Eye and Averaged for Both Eyes of a Participant at Week 13 | Wetting distance for Study eye: Change at Week 13 | 1.7 mm | Standard Deviation 6.59 |
| Restasis 0.05% | Change From Baseline in Mean Anesthetized Schirmer's Test Values (Distance of Strips Wetting) in the Study Eye and Averaged for Both Eyes of a Participant at Week 13 | Wetting distance for both eyes: Change at Week 13 | 2.59 mm | Standard Deviation 5.29 |
| Restasis 0.05% | Change From Baseline in Mean Anesthetized Schirmer's Test Values (Distance of Strips Wetting) in the Study Eye and Averaged for Both Eyes of a Participant at Week 13 | Wetting distance for Study eye: Change at Week 13 | 2.5 mm | Standard Deviation 5.55 |
| Restasis 0.05% | Change From Baseline in Mean Anesthetized Schirmer's Test Values (Distance of Strips Wetting) in the Study Eye and Averaged for Both Eyes of a Participant at Week 13 | Wetting distance for both eyes: Baseline | 6.76 mm | Standard Deviation 1.9 |
| Restasis 0.05% | Change From Baseline in Mean Anesthetized Schirmer's Test Values (Distance of Strips Wetting) in the Study Eye and Averaged for Both Eyes of a Participant at Week 13 | Wetting distance for Study eye: Baseline | 6.6 mm | Standard Deviation 2.08 |
Secondary
Change From Baseline in Mean Corneal Total Fluorescein Staining Score for the Study Eye and Averaged for Both Eyes at Week 12
Fluorescein Corneal Staining indicates the damage to the corneal epithelium (corneal epitheliopathy). Punctate corneal staining with fluorescein was evaluated and graded according to the NEI grading method. The cornea was divided into 5 regions: central, superior, inferior, nasal and temporal. Each of these 5 regions was graded from scores 0 to 3, where 0 indicated no staining (absent) and 3 maximal staining (severe damage). The total score was the sum of all these regions, ranged from 0 (absence of corneal epitheliopathy) to 15 (severe corneal epitheliopathy).
Time frame: Baseline, Week 12
Population: ITT population included all randomized participants. Here, 'Number analyzed' signifies participants evaluable for specified categories.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Lotemax Gel 0.5% and Restasis 0.05% | Change From Baseline in Mean Corneal Total Fluorescein Staining Score for the Study Eye and Averaged for Both Eyes at Week 12 | Score for study eye: Baseline | 5.6 units on a scale | Standard Deviation 1.92 |
| Lotemax Gel 0.5% and Restasis 0.05% | Change From Baseline in Mean Corneal Total Fluorescein Staining Score for the Study Eye and Averaged for Both Eyes at Week 12 | Score for study eye: Change at Week 12 | -1.3 units on a scale | Standard Deviation 2.3 |
| Lotemax Gel 0.5% and Restasis 0.05% | Change From Baseline in Mean Corneal Total Fluorescein Staining Score for the Study Eye and Averaged for Both Eyes at Week 12 | Score for both eyes: Baseline | 5.02 units on a scale | Standard Deviation 1.637 |
| Lotemax Gel 0.5% and Restasis 0.05% | Change From Baseline in Mean Corneal Total Fluorescein Staining Score for the Study Eye and Averaged for Both Eyes at Week 12 | Score for both eyes: Change at Week 12 | -0.66 units on a scale | Standard Deviation 1.809 |
| Lotemax Gel 0.5% | Change From Baseline in Mean Corneal Total Fluorescein Staining Score for the Study Eye and Averaged for Both Eyes at Week 12 | Score for both eyes: Change at Week 12 | -0.69 units on a scale | Standard Deviation 2.4 |
| Lotemax Gel 0.5% | Change From Baseline in Mean Corneal Total Fluorescein Staining Score for the Study Eye and Averaged for Both Eyes at Week 12 | Score for study eye: Baseline | 5.7 units on a scale | Standard Deviation 2.19 |
| Lotemax Gel 0.5% | Change From Baseline in Mean Corneal Total Fluorescein Staining Score for the Study Eye and Averaged for Both Eyes at Week 12 | Score for both eyes: Baseline | 5.22 units on a scale | Standard Deviation 1.955 |
| Lotemax Gel 0.5% | Change From Baseline in Mean Corneal Total Fluorescein Staining Score for the Study Eye and Averaged for Both Eyes at Week 12 | Score for study eye: Change at Week 12 | -0.7 units on a scale | Standard Deviation 3.01 |
| Restasis 0.05% | Change From Baseline in Mean Corneal Total Fluorescein Staining Score for the Study Eye and Averaged for Both Eyes at Week 12 | Score for both eyes: Change at Week 12 | -1.17 units on a scale | Standard Deviation 2.207 |
| Restasis 0.05% | Change From Baseline in Mean Corneal Total Fluorescein Staining Score for the Study Eye and Averaged for Both Eyes at Week 12 | Score for study eye: Change at Week 12 | -1.6 units on a scale | Standard Deviation 2.46 |
| Restasis 0.05% | Change From Baseline in Mean Corneal Total Fluorescein Staining Score for the Study Eye and Averaged for Both Eyes at Week 12 | Score for both eyes: Baseline | 5.08 units on a scale | Standard Deviation 1.896 |
| Restasis 0.05% | Change From Baseline in Mean Corneal Total Fluorescein Staining Score for the Study Eye and Averaged for Both Eyes at Week 12 | Score for study eye: Baseline | 5.5 units on a scale | Standard Deviation 1.97 |
Secondary
Change From Baseline in Mean Eye Comfort Index Questionnaire Total Score and Individual Question Scores at Week 12
An ocular comfort assessment questionnaire was administered at weeks 2, 4, and 12 to participants. The assessment of the degree of dry eye discomfort experienced by the participant was conducted using an adapted and validated 12-item ocular comfort questionnaire ( to measure the frequency and intensity of 6 common dry eye symptoms: dryness, grittiness, stinging, eye tiredness, pain, and itching) based upon the ocular comfort index of Johnson and Murphy. Each item (question) was graded from 0 to 4, where 0 = Not at all, 1 = Seldom; perceptible but not intense, 2 = Sometimes; intermittent with easily tolerable intensity, 3 = Frequently; often but with tolerable intensity, 4 = Constantly; constant or intolerable intensity. Total score was calculated and normalized to a score of 0 (no discomfort)-100 (more ocular discomfort) by the formula: Normalized comfort grade = (\[Total Comfort Grade\] \* 100)/48.
Time frame: Baseline, Week 12
Population: ITT population included all randomized participants. Here, 'Number analyzed' signifies participants evaluable for specified categories.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Lotemax Gel 0.5% and Restasis 0.05% | Change From Baseline in Mean Eye Comfort Index Questionnaire Total Score and Individual Question Scores at Week 12 | Grittiness intensity: Baseline | 1.6 units on a scale | Standard Deviation 1.06 |
| Lotemax Gel 0.5% and Restasis 0.05% | Change From Baseline in Mean Eye Comfort Index Questionnaire Total Score and Individual Question Scores at Week 12 | Dryness: Change at Week 12 | -0.4 units on a scale | Standard Deviation 0.92 |
| Lotemax Gel 0.5% and Restasis 0.05% | Change From Baseline in Mean Eye Comfort Index Questionnaire Total Score and Individual Question Scores at Week 12 | Dryness intensity: Baseline | 2.2 units on a scale | Standard Deviation 0.93 |
| Lotemax Gel 0.5% and Restasis 0.05% | Change From Baseline in Mean Eye Comfort Index Questionnaire Total Score and Individual Question Scores at Week 12 | Dryness intensity: Change at Week 12 | -0.5 units on a scale | Standard Deviation 0.93 |
| Lotemax Gel 0.5% and Restasis 0.05% | Change From Baseline in Mean Eye Comfort Index Questionnaire Total Score and Individual Question Scores at Week 12 | Grittiness: Baseline | 1.5 units on a scale | Standard Deviation 0.9 |
| Lotemax Gel 0.5% and Restasis 0.05% | Change From Baseline in Mean Eye Comfort Index Questionnaire Total Score and Individual Question Scores at Week 12 | Grittiness: Change at Week 12 | -0.4 units on a scale | Standard Deviation 0.97 |
| Lotemax Gel 0.5% and Restasis 0.05% | Change From Baseline in Mean Eye Comfort Index Questionnaire Total Score and Individual Question Scores at Week 12 | Dryness: Baseline | 2.3 units on a scale | Standard Deviation 0.85 |
| Lotemax Gel 0.5% and Restasis 0.05% | Change From Baseline in Mean Eye Comfort Index Questionnaire Total Score and Individual Question Scores at Week 12 | Grittiness intensity: Change at Week 12 | -0.5 units on a scale | Standard Deviation 0.96 |
| Lotemax Gel 0.5% and Restasis 0.05% | Change From Baseline in Mean Eye Comfort Index Questionnaire Total Score and Individual Question Scores at Week 12 | Stinging: Baseline | 1.3 units on a scale | Standard Deviation 1.07 |
| Lotemax Gel 0.5% and Restasis 0.05% | Change From Baseline in Mean Eye Comfort Index Questionnaire Total Score and Individual Question Scores at Week 12 | Stinging: Change at Week 12 | -0.2 units on a scale | Standard Deviation 1.17 |
| Lotemax Gel 0.5% and Restasis 0.05% | Change From Baseline in Mean Eye Comfort Index Questionnaire Total Score and Individual Question Scores at Week 12 | Stinging intensity: Baseline | 1.2 units on a scale | Standard Deviation 1.06 |
| Lotemax Gel 0.5% and Restasis 0.05% | Change From Baseline in Mean Eye Comfort Index Questionnaire Total Score and Individual Question Scores at Week 12 | Stinging intensity: Change at Week 12 | -0.2 units on a scale | Standard Deviation 0.93 |
| Lotemax Gel 0.5% and Restasis 0.05% | Change From Baseline in Mean Eye Comfort Index Questionnaire Total Score and Individual Question Scores at Week 12 | Tiredness: Baseline | 1.8 units on a scale | Standard Deviation 1.01 |
| Lotemax Gel 0.5% and Restasis 0.05% | Change From Baseline in Mean Eye Comfort Index Questionnaire Total Score and Individual Question Scores at Week 12 | Tiredness: Change at Week 12 | -0.4 units on a scale | Standard Deviation 1.11 |
| Lotemax Gel 0.5% and Restasis 0.05% | Change From Baseline in Mean Eye Comfort Index Questionnaire Total Score and Individual Question Scores at Week 12 | Tiredness intensity: Baseline | 1.7 units on a scale | Standard Deviation 1.02 |
| Lotemax Gel 0.5% and Restasis 0.05% | Change From Baseline in Mean Eye Comfort Index Questionnaire Total Score and Individual Question Scores at Week 12 | Tiredness intensity: Change at Week 12 | -0.3 units on a scale | Standard Deviation 1.03 |
| Lotemax Gel 0.5% and Restasis 0.05% | Change From Baseline in Mean Eye Comfort Index Questionnaire Total Score and Individual Question Scores at Week 12 | Pain: Baseline | 0.9 units on a scale | Standard Deviation 0.89 |
| Lotemax Gel 0.5% and Restasis 0.05% | Change From Baseline in Mean Eye Comfort Index Questionnaire Total Score and Individual Question Scores at Week 12 | Pain: Change at Week 12 | -0.2 units on a scale | Standard Deviation 0.92 |
| Lotemax Gel 0.5% and Restasis 0.05% | Change From Baseline in Mean Eye Comfort Index Questionnaire Total Score and Individual Question Scores at Week 12 | Pain intensity: Baseline | 0.9 units on a scale | Standard Deviation 0.98 |
| Lotemax Gel 0.5% and Restasis 0.05% | Change From Baseline in Mean Eye Comfort Index Questionnaire Total Score and Individual Question Scores at Week 12 | Pain intensity: Change at Week 12 | -0.1 units on a scale | Standard Deviation 1.02 |
| Lotemax Gel 0.5% and Restasis 0.05% | Change From Baseline in Mean Eye Comfort Index Questionnaire Total Score and Individual Question Scores at Week 12 | Itch: Baseline | 1.5 units on a scale | Standard Deviation 1.03 |
| Lotemax Gel 0.5% and Restasis 0.05% | Change From Baseline in Mean Eye Comfort Index Questionnaire Total Score and Individual Question Scores at Week 12 | Itch: Change at Week 12 | -0.2 units on a scale | Standard Deviation 1.34 |
| Lotemax Gel 0.5% and Restasis 0.05% | Change From Baseline in Mean Eye Comfort Index Questionnaire Total Score and Individual Question Scores at Week 12 | Itch intensity: Baseline | 1.5 units on a scale | Standard Deviation 1.03 |
| Lotemax Gel 0.5% and Restasis 0.05% | Change From Baseline in Mean Eye Comfort Index Questionnaire Total Score and Individual Question Scores at Week 12 | Itch intensity: Change at Week 12 | -0.2 units on a scale | Standard Deviation 1.19 |
| Lotemax Gel 0.5% and Restasis 0.05% | Change From Baseline in Mean Eye Comfort Index Questionnaire Total Score and Individual Question Scores at Week 12 | Total comfort score: Baseline | 38.4 units on a scale | Standard Deviation 16.39 |
| Lotemax Gel 0.5% and Restasis 0.05% | Change From Baseline in Mean Eye Comfort Index Questionnaire Total Score and Individual Question Scores at Week 12 | Total comfort score: Change at Week 12 | -7.2 units on a scale | Standard Deviation 17.16 |
| Lotemax Gel 0.5% | Change From Baseline in Mean Eye Comfort Index Questionnaire Total Score and Individual Question Scores at Week 12 | Stinging: Baseline | 1.2 units on a scale | Standard Deviation 1.15 |
| Lotemax Gel 0.5% | Change From Baseline in Mean Eye Comfort Index Questionnaire Total Score and Individual Question Scores at Week 12 | Itch: Baseline | 1.6 units on a scale | Standard Deviation 1.16 |
| Lotemax Gel 0.5% | Change From Baseline in Mean Eye Comfort Index Questionnaire Total Score and Individual Question Scores at Week 12 | Stinging: Change at Week 12 | -0.4 units on a scale | Standard Deviation 1.13 |
| Lotemax Gel 0.5% | Change From Baseline in Mean Eye Comfort Index Questionnaire Total Score and Individual Question Scores at Week 12 | Stinging intensity: Baseline | 1.3 units on a scale | Standard Deviation 1.16 |
| Lotemax Gel 0.5% | Change From Baseline in Mean Eye Comfort Index Questionnaire Total Score and Individual Question Scores at Week 12 | Total comfort score: Baseline | 37.8 units on a scale | Standard Deviation 16.99 |
| Lotemax Gel 0.5% | Change From Baseline in Mean Eye Comfort Index Questionnaire Total Score and Individual Question Scores at Week 12 | Stinging intensity: Change at Week 12 | -0.4 units on a scale | Standard Deviation 1.11 |
| Lotemax Gel 0.5% | Change From Baseline in Mean Eye Comfort Index Questionnaire Total Score and Individual Question Scores at Week 12 | Itch: Change at Week 12 | -0.7 units on a scale | Standard Deviation 1.32 |
| Lotemax Gel 0.5% | Change From Baseline in Mean Eye Comfort Index Questionnaire Total Score and Individual Question Scores at Week 12 | Tiredness: Baseline | 1.6 units on a scale | Standard Deviation 0.93 |
| Lotemax Gel 0.5% | Change From Baseline in Mean Eye Comfort Index Questionnaire Total Score and Individual Question Scores at Week 12 | Tiredness: Change at Week 12 | -0.2 units on a scale | Standard Deviation 0.77 |
| Lotemax Gel 0.5% | Change From Baseline in Mean Eye Comfort Index Questionnaire Total Score and Individual Question Scores at Week 12 | Tiredness intensity: Baseline | 1.6 units on a scale | Standard Deviation 1.02 |
| Lotemax Gel 0.5% | Change From Baseline in Mean Eye Comfort Index Questionnaire Total Score and Individual Question Scores at Week 12 | Itch intensity: Baseline | 1.5 units on a scale | Standard Deviation 1.16 |
| Lotemax Gel 0.5% | Change From Baseline in Mean Eye Comfort Index Questionnaire Total Score and Individual Question Scores at Week 12 | Tiredness intensity: Change at Week 12 | -0.2 units on a scale | Standard Deviation 0.9 |
| Lotemax Gel 0.5% | Change From Baseline in Mean Eye Comfort Index Questionnaire Total Score and Individual Question Scores at Week 12 | Pain: Baseline | 0.8 units on a scale | Standard Deviation 0.81 |
| Lotemax Gel 0.5% | Change From Baseline in Mean Eye Comfort Index Questionnaire Total Score and Individual Question Scores at Week 12 | Pain: Change at Week 12 | -0.2 units on a scale | Standard Deviation 0.96 |
| Lotemax Gel 0.5% | Change From Baseline in Mean Eye Comfort Index Questionnaire Total Score and Individual Question Scores at Week 12 | Dryness: Baseline | 2.2 units on a scale | Standard Deviation 0.81 |
| Lotemax Gel 0.5% | Change From Baseline in Mean Eye Comfort Index Questionnaire Total Score and Individual Question Scores at Week 12 | Dryness: Change at Week 12 | -0.1 units on a scale | Standard Deviation 0.99 |
| Lotemax Gel 0.5% | Change From Baseline in Mean Eye Comfort Index Questionnaire Total Score and Individual Question Scores at Week 12 | Itch intensity: Change at Week 12 | -0.7 units on a scale | Standard Deviation 1.22 |
| Lotemax Gel 0.5% | Change From Baseline in Mean Eye Comfort Index Questionnaire Total Score and Individual Question Scores at Week 12 | Dryness intensity: Baseline | 2.1 units on a scale | Standard Deviation 0.9 |
| Lotemax Gel 0.5% | Change From Baseline in Mean Eye Comfort Index Questionnaire Total Score and Individual Question Scores at Week 12 | Pain intensity: Baseline | 0.8 units on a scale | Standard Deviation 0.97 |
| Lotemax Gel 0.5% | Change From Baseline in Mean Eye Comfort Index Questionnaire Total Score and Individual Question Scores at Week 12 | Dryness intensity: Change at Week 12 | -0.3 units on a scale | Standard Deviation 1.06 |
| Lotemax Gel 0.5% | Change From Baseline in Mean Eye Comfort Index Questionnaire Total Score and Individual Question Scores at Week 12 | Grittiness: Baseline | 1.7 units on a scale | Standard Deviation 1.09 |
| Lotemax Gel 0.5% | Change From Baseline in Mean Eye Comfort Index Questionnaire Total Score and Individual Question Scores at Week 12 | Grittiness: Change at Week 12 | -0.6 units on a scale | Standard Deviation 0.95 |
| Lotemax Gel 0.5% | Change From Baseline in Mean Eye Comfort Index Questionnaire Total Score and Individual Question Scores at Week 12 | Pain intensity: Change at Week 12 | -0.3 units on a scale | Standard Deviation 1.07 |
| Lotemax Gel 0.5% | Change From Baseline in Mean Eye Comfort Index Questionnaire Total Score and Individual Question Scores at Week 12 | Grittiness intensity: Baseline | 1.6 units on a scale | Standard Deviation 0.93 |
| Lotemax Gel 0.5% | Change From Baseline in Mean Eye Comfort Index Questionnaire Total Score and Individual Question Scores at Week 12 | Grittiness intensity: Change at Week 12 | -0.6 units on a scale | Standard Deviation 0.96 |
| Lotemax Gel 0.5% | Change From Baseline in Mean Eye Comfort Index Questionnaire Total Score and Individual Question Scores at Week 12 | Total comfort score: Change at Week 12 | -10.0 units on a scale | Standard Deviation 16.35 |
| Restasis 0.05% | Change From Baseline in Mean Eye Comfort Index Questionnaire Total Score and Individual Question Scores at Week 12 | Grittiness intensity: Baseline | 1.3 units on a scale | Standard Deviation 0.98 |
| Restasis 0.05% | Change From Baseline in Mean Eye Comfort Index Questionnaire Total Score and Individual Question Scores at Week 12 | Grittiness: Baseline | 1.4 units on a scale | Standard Deviation 0.97 |
| Restasis 0.05% | Change From Baseline in Mean Eye Comfort Index Questionnaire Total Score and Individual Question Scores at Week 12 | Dryness: Baseline | 2.2 units on a scale | Standard Deviation 0.93 |
| Restasis 0.05% | Change From Baseline in Mean Eye Comfort Index Questionnaire Total Score and Individual Question Scores at Week 12 | Stinging: Change at Week 12 | -0.1 units on a scale | Standard Deviation 1.38 |
| Restasis 0.05% | Change From Baseline in Mean Eye Comfort Index Questionnaire Total Score and Individual Question Scores at Week 12 | Itch: Baseline | 1.2 units on a scale | Standard Deviation 0.99 |
| Restasis 0.05% | Change From Baseline in Mean Eye Comfort Index Questionnaire Total Score and Individual Question Scores at Week 12 | Pain: Change at Week 12 | -0.2 units on a scale | Standard Deviation 0.76 |
| Restasis 0.05% | Change From Baseline in Mean Eye Comfort Index Questionnaire Total Score and Individual Question Scores at Week 12 | Stinging intensity: Baseline | 1.0 units on a scale | Standard Deviation 0.85 |
| Restasis 0.05% | Change From Baseline in Mean Eye Comfort Index Questionnaire Total Score and Individual Question Scores at Week 12 | Itch intensity: Change at Week 12 | -0.3 units on a scale | Standard Deviation 1.1 |
| Restasis 0.05% | Change From Baseline in Mean Eye Comfort Index Questionnaire Total Score and Individual Question Scores at Week 12 | Dryness: Change at Week 12 | -0.4 units on a scale | Standard Deviation 0.87 |
| Restasis 0.05% | Change From Baseline in Mean Eye Comfort Index Questionnaire Total Score and Individual Question Scores at Week 12 | Stinging intensity: Change at Week 12 | -0.1 units on a scale | Standard Deviation 1.23 |
| Restasis 0.05% | Change From Baseline in Mean Eye Comfort Index Questionnaire Total Score and Individual Question Scores at Week 12 | Pain intensity: Change at Week 12 | -0.3 units on a scale | Standard Deviation 0.74 |
| Restasis 0.05% | Change From Baseline in Mean Eye Comfort Index Questionnaire Total Score and Individual Question Scores at Week 12 | Grittiness: Change at Week 12 | -0.6 units on a scale | Standard Deviation 1.06 |
| Restasis 0.05% | Change From Baseline in Mean Eye Comfort Index Questionnaire Total Score and Individual Question Scores at Week 12 | Tiredness: Baseline | 1.9 units on a scale | Standard Deviation 1.02 |
| Restasis 0.05% | Change From Baseline in Mean Eye Comfort Index Questionnaire Total Score and Individual Question Scores at Week 12 | Itch: Change at Week 12 | -0.2 units on a scale | Standard Deviation 1.07 |
| Restasis 0.05% | Change From Baseline in Mean Eye Comfort Index Questionnaire Total Score and Individual Question Scores at Week 12 | Dryness intensity: Baseline | 2.2 units on a scale | Standard Deviation 0.92 |
| Restasis 0.05% | Change From Baseline in Mean Eye Comfort Index Questionnaire Total Score and Individual Question Scores at Week 12 | Tiredness: Change at Week 12 | -0.4 units on a scale | Standard Deviation 0.83 |
| Restasis 0.05% | Change From Baseline in Mean Eye Comfort Index Questionnaire Total Score and Individual Question Scores at Week 12 | Total comfort score: Baseline | 34.8 units on a scale | Standard Deviation 14.06 |
| Restasis 0.05% | Change From Baseline in Mean Eye Comfort Index Questionnaire Total Score and Individual Question Scores at Week 12 | Stinging: Baseline | 1.0 units on a scale | Standard Deviation 0.79 |
| Restasis 0.05% | Change From Baseline in Mean Eye Comfort Index Questionnaire Total Score and Individual Question Scores at Week 12 | Tiredness intensity: Baseline | 1.8 units on a scale | Standard Deviation 1 |
| Restasis 0.05% | Change From Baseline in Mean Eye Comfort Index Questionnaire Total Score and Individual Question Scores at Week 12 | Grittiness intensity: Change at Week 12 | -0.5 units on a scale | Standard Deviation 1.03 |
| Restasis 0.05% | Change From Baseline in Mean Eye Comfort Index Questionnaire Total Score and Individual Question Scores at Week 12 | Dryness intensity: Change at Week 12 | -0.6 units on a scale | Standard Deviation 1.08 |
| Restasis 0.05% | Change From Baseline in Mean Eye Comfort Index Questionnaire Total Score and Individual Question Scores at Week 12 | Tiredness intensity: Change at Week 12 | -0.4 units on a scale | Standard Deviation 0.7 |
| Restasis 0.05% | Change From Baseline in Mean Eye Comfort Index Questionnaire Total Score and Individual Question Scores at Week 12 | Itch intensity: Baseline | 1.2 units on a scale | Standard Deviation 1.09 |
| Restasis 0.05% | Change From Baseline in Mean Eye Comfort Index Questionnaire Total Score and Individual Question Scores at Week 12 | Pain intensity: Baseline | 0.8 units on a scale | Standard Deviation 0.88 |
| Restasis 0.05% | Change From Baseline in Mean Eye Comfort Index Questionnaire Total Score and Individual Question Scores at Week 12 | Pain: Baseline | 0.7 units on a scale | Standard Deviation 0.69 |
| Restasis 0.05% | Change From Baseline in Mean Eye Comfort Index Questionnaire Total Score and Individual Question Scores at Week 12 | Total comfort score: Change at Week 12 | -8.6 units on a scale | Standard Deviation 14.48 |
Secondary
Change From Baseline in Mean Eye Dryness Questionnaire Total and Individual Question Scores at Week 12
The 5-item Dry Eye Questionnaire (DEQ-5) is a validated questionnaire for discriminating self-assessed severity of dry eye diagnoses. The participants rated the frequency on a scale of 0 (never) to 4 (constant) with which they have experienced 3 symptoms (watery eyes, discomfort and dryness). The participant was also asked to rate the increase in intensity of discomfort and dryness throughout the day on a scale of 0 (never have it) to 5 (very intense). Participant rated the overall severity of dry eye symptoms on a scale of 0 (no problem) to 4 (intolerable; unable to perform my daily tasks). Total DEQ-5 score was the sum of scores for frequency and intensity of dryness and discomfort plus frequency of watery eyes. A DEQ-5 total score \>6 was indicative of DED and a score \>12 is indicative of Sjögren's syndrome.
Time frame: Baseline, Week 12
Population: ITT population included all randomized participants. Here, 'Number analyzed' signifies participants evaluable for specified categories.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Lotemax Gel 0.5% and Restasis 0.05% | Change From Baseline in Mean Eye Dryness Questionnaire Total and Individual Question Scores at Week 12 | Discomfort frequency: Baseline | 2.2 units on a scale | Standard Deviation 0.81 |
| Lotemax Gel 0.5% and Restasis 0.05% | Change From Baseline in Mean Eye Dryness Questionnaire Total and Individual Question Scores at Week 12 | Watery eyes frequency: Change at Week 12 | -0.4 units on a scale | Standard Deviation 1.14 |
| Lotemax Gel 0.5% and Restasis 0.05% | Change From Baseline in Mean Eye Dryness Questionnaire Total and Individual Question Scores at Week 12 | Dryness frequency: Change at Week 12 | -0.6 units on a scale | Standard Deviation 0.8 |
| Lotemax Gel 0.5% and Restasis 0.05% | Change From Baseline in Mean Eye Dryness Questionnaire Total and Individual Question Scores at Week 12 | Total score: Baseline | 11.0 units on a scale | Standard Deviation 3.6 |
| Lotemax Gel 0.5% and Restasis 0.05% | Change From Baseline in Mean Eye Dryness Questionnaire Total and Individual Question Scores at Week 12 | Watery eyes frequency: Baseline | 1.5 units on a scale | Standard Deviation 1 |
| Lotemax Gel 0.5% and Restasis 0.05% | Change From Baseline in Mean Eye Dryness Questionnaire Total and Individual Question Scores at Week 12 | Dryness intensity: Baseline | 2.4 units on a scale | Standard Deviation 1.15 |
| Lotemax Gel 0.5% and Restasis 0.05% | Change From Baseline in Mean Eye Dryness Questionnaire Total and Individual Question Scores at Week 12 | Discomfort intensity: Baseline | 2.4 units on a scale | Standard Deviation 1.14 |
| Lotemax Gel 0.5% and Restasis 0.05% | Change From Baseline in Mean Eye Dryness Questionnaire Total and Individual Question Scores at Week 12 | Dryness intensity: Change at Week 12 | -0.2 units on a scale | Standard Deviation 1.31 |
| Lotemax Gel 0.5% and Restasis 0.05% | Change From Baseline in Mean Eye Dryness Questionnaire Total and Individual Question Scores at Week 12 | Total score: Change at Week 12 | -2.0 units on a scale | Standard Deviation 3.52 |
| Lotemax Gel 0.5% and Restasis 0.05% | Change From Baseline in Mean Eye Dryness Questionnaire Total and Individual Question Scores at Week 12 | Overall severity: Change at Week 12 | -0.6 units on a scale | Standard Deviation 0.92 |
| Lotemax Gel 0.5% and Restasis 0.05% | Change From Baseline in Mean Eye Dryness Questionnaire Total and Individual Question Scores at Week 12 | Discomfort intensity: Change at Week 12 | -0.4 units on a scale | Standard Deviation 1.2 |
| Lotemax Gel 0.5% and Restasis 0.05% | Change From Baseline in Mean Eye Dryness Questionnaire Total and Individual Question Scores at Week 12 | Discomfort frequency: Change at Week 12 | -0.4 units on a scale | Standard Deviation 0.67 |
| Lotemax Gel 0.5% and Restasis 0.05% | Change From Baseline in Mean Eye Dryness Questionnaire Total and Individual Question Scores at Week 12 | Overall severity: Baseline | 1.9 units on a scale | Standard Deviation 0.77 |
| Lotemax Gel 0.5% and Restasis 0.05% | Change From Baseline in Mean Eye Dryness Questionnaire Total and Individual Question Scores at Week 12 | Dryness frequency: Baseline | 2.4 units on a scale | Standard Deviation 0.79 |
| Lotemax Gel 0.5% | Change From Baseline in Mean Eye Dryness Questionnaire Total and Individual Question Scores at Week 12 | Watery eyes frequency: Baseline | 1.3 units on a scale | Standard Deviation 1.03 |
| Lotemax Gel 0.5% | Change From Baseline in Mean Eye Dryness Questionnaire Total and Individual Question Scores at Week 12 | Discomfort frequency: Baseline | 2.1 units on a scale | Standard Deviation 0.67 |
| Lotemax Gel 0.5% | Change From Baseline in Mean Eye Dryness Questionnaire Total and Individual Question Scores at Week 12 | Discomfort frequency: Change at Week 12 | -0.2 units on a scale | Standard Deviation 0.97 |
| Lotemax Gel 0.5% | Change From Baseline in Mean Eye Dryness Questionnaire Total and Individual Question Scores at Week 12 | Discomfort intensity: Baseline | 2.5 units on a scale | Standard Deviation 1.03 |
| Lotemax Gel 0.5% | Change From Baseline in Mean Eye Dryness Questionnaire Total and Individual Question Scores at Week 12 | Discomfort intensity: Change at Week 12 | -0.5 units on a scale | Standard Deviation 0.85 |
| Lotemax Gel 0.5% | Change From Baseline in Mean Eye Dryness Questionnaire Total and Individual Question Scores at Week 12 | Dryness frequency: Baseline | 2.1 units on a scale | Standard Deviation 0.82 |
| Lotemax Gel 0.5% | Change From Baseline in Mean Eye Dryness Questionnaire Total and Individual Question Scores at Week 12 | Dryness frequency: Change at Week 12 | -0.1 units on a scale | Standard Deviation 0.83 |
| Lotemax Gel 0.5% | Change From Baseline in Mean Eye Dryness Questionnaire Total and Individual Question Scores at Week 12 | Dryness intensity: Baseline | 2.8 units on a scale | Standard Deviation 1.08 |
| Lotemax Gel 0.5% | Change From Baseline in Mean Eye Dryness Questionnaire Total and Individual Question Scores at Week 12 | Dryness intensity: Change at Week 12 | -0.7 units on a scale | Standard Deviation 0.83 |
| Lotemax Gel 0.5% | Change From Baseline in Mean Eye Dryness Questionnaire Total and Individual Question Scores at Week 12 | Overall severity: Baseline | 1.8 units on a scale | Standard Deviation 0.82 |
| Lotemax Gel 0.5% | Change From Baseline in Mean Eye Dryness Questionnaire Total and Individual Question Scores at Week 12 | Watery eyes frequency: Change at Week 12 | -0.4 units on a scale | Standard Deviation 0.77 |
| Lotemax Gel 0.5% | Change From Baseline in Mean Eye Dryness Questionnaire Total and Individual Question Scores at Week 12 | Overall severity: Change at Week 12 | -0.4 units on a scale | Standard Deviation 0.97 |
| Lotemax Gel 0.5% | Change From Baseline in Mean Eye Dryness Questionnaire Total and Individual Question Scores at Week 12 | Total score: Baseline | 10.8 units on a scale | Standard Deviation 3.38 |
| Lotemax Gel 0.5% | Change From Baseline in Mean Eye Dryness Questionnaire Total and Individual Question Scores at Week 12 | Total score: Change at Week 12 | -2.0 units on a scale | Standard Deviation 2.81 |
| Restasis 0.05% | Change From Baseline in Mean Eye Dryness Questionnaire Total and Individual Question Scores at Week 12 | Dryness frequency: Baseline | 2.4 units on a scale | Standard Deviation 1 |
| Restasis 0.05% | Change From Baseline in Mean Eye Dryness Questionnaire Total and Individual Question Scores at Week 12 | Total score: Baseline | 10.6 units on a scale | Standard Deviation 4.55 |
| Restasis 0.05% | Change From Baseline in Mean Eye Dryness Questionnaire Total and Individual Question Scores at Week 12 | Watery eyes frequency: Change at Week 12 | 0.0 units on a scale | Standard Deviation 1.37 |
| Restasis 0.05% | Change From Baseline in Mean Eye Dryness Questionnaire Total and Individual Question Scores at Week 12 | Discomfort intensity: Change at Week 12 | -0.4 units on a scale | Standard Deviation 1.11 |
| Restasis 0.05% | Change From Baseline in Mean Eye Dryness Questionnaire Total and Individual Question Scores at Week 12 | Overall severity: Baseline | 1.8 units on a scale | Standard Deviation 0.79 |
| Restasis 0.05% | Change From Baseline in Mean Eye Dryness Questionnaire Total and Individual Question Scores at Week 12 | Discomfort intensity: Baseline | 2.4 units on a scale | Standard Deviation 1.22 |
| Restasis 0.05% | Change From Baseline in Mean Eye Dryness Questionnaire Total and Individual Question Scores at Week 12 | Discomfort frequency: Baseline | 2.1 units on a scale | Standard Deviation 0.82 |
| Restasis 0.05% | Change From Baseline in Mean Eye Dryness Questionnaire Total and Individual Question Scores at Week 12 | Overall severity: Change at Week 12 | -0.5 units on a scale | Standard Deviation 0.71 |
| Restasis 0.05% | Change From Baseline in Mean Eye Dryness Questionnaire Total and Individual Question Scores at Week 12 | Dryness intensity: Baseline | 2.3 units on a scale | Standard Deviation 1.27 |
| Restasis 0.05% | Change From Baseline in Mean Eye Dryness Questionnaire Total and Individual Question Scores at Week 12 | Discomfort frequency: Change at Week 12 | -0.3 units on a scale | Standard Deviation 0.94 |
| Restasis 0.05% | Change From Baseline in Mean Eye Dryness Questionnaire Total and Individual Question Scores at Week 12 | Dryness intensity: Change at Week 12 | -0.4 units on a scale | Standard Deviation 1.32 |
| Restasis 0.05% | Change From Baseline in Mean Eye Dryness Questionnaire Total and Individual Question Scores at Week 12 | Dryness frequency: Change at Week 12 | -0.6 units on a scale | Standard Deviation 1 |
| Restasis 0.05% | Change From Baseline in Mean Eye Dryness Questionnaire Total and Individual Question Scores at Week 12 | Total score: Change at Week 12 | -1.6 units on a scale | Standard Deviation 4.08 |
| Restasis 0.05% | Change From Baseline in Mean Eye Dryness Questionnaire Total and Individual Question Scores at Week 12 | Watery eyes frequency: Baseline | 1.3 units on a scale | Standard Deviation 1.16 |
Secondary
Change From Baseline in Mean Non-Invasive Keratographic Tear Film Breakup Time (NIKBUT) of the Study Eye and Averaged for Both Eyes of a Participant at Week 12
The tear film breakup time was defined as the interval between the last complete blink and the first appearance of dark zones or spots, or disruption in the tear film. Tear film examination using any non-invasive method analyzes optical reflections from the cornea. Reflections that become distorted are characteristic of tear film breakup. Circular images were projected onto the corneal surface using an Oculus Keratograph 5M instrument, and the tear film reflection was observed on a computer. NIKBUT (initial break-up time \[NIKBUTi\] and average break-up time \[NIKBUTav\]) were determined and recorded for each eye in duplicate after participant blink 2 times. NIKBUT at Baseline (Day 0) was subtracted from NIKBUT at Week 12 (Day 84) and reported as change. A higher number represented a lengthening in the NIKBUT. A longer NIKBUT indicated a more stable tear film.
Time frame: Baseline, Week 12
Population: ITT population included all randomized participants. Here, 'Number analyzed' signifies participants evaluable for specified categories.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Lotemax Gel 0.5% and Restasis 0.05% | Change From Baseline in Mean Non-Invasive Keratographic Tear Film Breakup Time (NIKBUT) of the Study Eye and Averaged for Both Eyes of a Participant at Week 12 | NIKBUTi for study eye: Baseline | 6.49 seconds | Standard Deviation 1.349 |
| Lotemax Gel 0.5% and Restasis 0.05% | Change From Baseline in Mean Non-Invasive Keratographic Tear Film Breakup Time (NIKBUT) of the Study Eye and Averaged for Both Eyes of a Participant at Week 12 | NIKBUTi for study eye: Change at Week 12 | 0.59 seconds | Standard Deviation 3.826 |
| Lotemax Gel 0.5% and Restasis 0.05% | Change From Baseline in Mean Non-Invasive Keratographic Tear Film Breakup Time (NIKBUT) of the Study Eye and Averaged for Both Eyes of a Participant at Week 12 | NIKBUTi for both eyes: Baseline | 6.92 seconds | Standard Deviation 2.175 |
| Lotemax Gel 0.5% and Restasis 0.05% | Change From Baseline in Mean Non-Invasive Keratographic Tear Film Breakup Time (NIKBUT) of the Study Eye and Averaged for Both Eyes of a Participant at Week 12 | NIKBUTi for both eyes: Change at Wee 12 | -0.14 seconds | Standard Deviation 2.774 |
| Lotemax Gel 0.5% and Restasis 0.05% | Change From Baseline in Mean Non-Invasive Keratographic Tear Film Breakup Time (NIKBUT) of the Study Eye and Averaged for Both Eyes of a Participant at Week 12 | NIKBUTav for study eye: Baseline | 9.57 seconds | Standard Deviation 3.018 |
| Lotemax Gel 0.5% and Restasis 0.05% | Change From Baseline in Mean Non-Invasive Keratographic Tear Film Breakup Time (NIKBUT) of the Study Eye and Averaged for Both Eyes of a Participant at Week 12 | NIKBUTav for study eye: Change at Week 12 | -0.01 seconds | Standard Deviation 2.806 |
| Lotemax Gel 0.5% and Restasis 0.05% | Change From Baseline in Mean Non-Invasive Keratographic Tear Film Breakup Time (NIKBUT) of the Study Eye and Averaged for Both Eyes of a Participant at Week 12 | NIKBUTav for both eyes: Baseline | 9.21 seconds | Standard Deviation 3.253 |
| Lotemax Gel 0.5% and Restasis 0.05% | Change From Baseline in Mean Non-Invasive Keratographic Tear Film Breakup Time (NIKBUT) of the Study Eye and Averaged for Both Eyes of a Participant at Week 12 | NIKBUTav for both eyes: Change at Week 12 | -0.04 seconds | Standard Deviation 1.882 |
| Lotemax Gel 0.5% | Change From Baseline in Mean Non-Invasive Keratographic Tear Film Breakup Time (NIKBUT) of the Study Eye and Averaged for Both Eyes of a Participant at Week 12 | NIKBUTi for both eyes: Baseline | 8.22 seconds | Standard Deviation 4.24 |
| Lotemax Gel 0.5% | Change From Baseline in Mean Non-Invasive Keratographic Tear Film Breakup Time (NIKBUT) of the Study Eye and Averaged for Both Eyes of a Participant at Week 12 | NIKBUTav for both eyes: Baseline | 10.99 seconds | Standard Deviation 3.969 |
| Lotemax Gel 0.5% | Change From Baseline in Mean Non-Invasive Keratographic Tear Film Breakup Time (NIKBUT) of the Study Eye and Averaged for Both Eyes of a Participant at Week 12 | NIKBUTi for both eyes: Change at Wee 12 | 0.17 seconds | Standard Deviation 3.511 |
| Lotemax Gel 0.5% | Change From Baseline in Mean Non-Invasive Keratographic Tear Film Breakup Time (NIKBUT) of the Study Eye and Averaged for Both Eyes of a Participant at Week 12 | NIKBUTav for study eye: Baseline | 11.20 seconds | Standard Deviation 3.164 |
| Lotemax Gel 0.5% | Change From Baseline in Mean Non-Invasive Keratographic Tear Film Breakup Time (NIKBUT) of the Study Eye and Averaged for Both Eyes of a Participant at Week 12 | NIKBUTav for study eye: Change at Week 12 | 1.55 seconds | Standard Deviation 5.453 |
| Lotemax Gel 0.5% | Change From Baseline in Mean Non-Invasive Keratographic Tear Film Breakup Time (NIKBUT) of the Study Eye and Averaged for Both Eyes of a Participant at Week 12 | NIKBUTi for study eye: Baseline | 8.11 seconds | Standard Deviation 3.531 |
| Lotemax Gel 0.5% | Change From Baseline in Mean Non-Invasive Keratographic Tear Film Breakup Time (NIKBUT) of the Study Eye and Averaged for Both Eyes of a Participant at Week 12 | NIKBUTi for study eye: Change at Week 12 | 1.09 seconds | Standard Deviation 5.833 |
| Lotemax Gel 0.5% | Change From Baseline in Mean Non-Invasive Keratographic Tear Film Breakup Time (NIKBUT) of the Study Eye and Averaged for Both Eyes of a Participant at Week 12 | NIKBUTav for both eyes: Change at Week 12 | 1.32 seconds | Standard Deviation 3.985 |
| Restasis 0.05% | Change From Baseline in Mean Non-Invasive Keratographic Tear Film Breakup Time (NIKBUT) of the Study Eye and Averaged for Both Eyes of a Participant at Week 12 | NIKBUTi for both eyes: Baseline | 7.60 seconds | Standard Deviation 4.896 |
| Restasis 0.05% | Change From Baseline in Mean Non-Invasive Keratographic Tear Film Breakup Time (NIKBUT) of the Study Eye and Averaged for Both Eyes of a Participant at Week 12 | NIKBUTi for study eye: Change at Week 12 | 0.31 seconds | Standard Deviation 6.356 |
| Restasis 0.05% | Change From Baseline in Mean Non-Invasive Keratographic Tear Film Breakup Time (NIKBUT) of the Study Eye and Averaged for Both Eyes of a Participant at Week 12 | NIKBUTi for study eye: Baseline | 7.18 seconds | Standard Deviation 4.867 |
| Restasis 0.05% | Change From Baseline in Mean Non-Invasive Keratographic Tear Film Breakup Time (NIKBUT) of the Study Eye and Averaged for Both Eyes of a Participant at Week 12 | NIKBUTi for both eyes: Change at Wee 12 | -1.08 seconds | Standard Deviation 4.77 |
| Restasis 0.05% | Change From Baseline in Mean Non-Invasive Keratographic Tear Film Breakup Time (NIKBUT) of the Study Eye and Averaged for Both Eyes of a Participant at Week 12 | NIKBUTav for both eyes: Baseline | 9.98 seconds | Standard Deviation 5.744 |
| Restasis 0.05% | Change From Baseline in Mean Non-Invasive Keratographic Tear Film Breakup Time (NIKBUT) of the Study Eye and Averaged for Both Eyes of a Participant at Week 12 | NIKBUTav for study eye: Change at Week 12 | 1.26 seconds | Standard Deviation 5.636 |
| Restasis 0.05% | Change From Baseline in Mean Non-Invasive Keratographic Tear Film Breakup Time (NIKBUT) of the Study Eye and Averaged for Both Eyes of a Participant at Week 12 | NIKBUTav for study eye: Baseline | 9.07 seconds | Standard Deviation 5.595 |
| Restasis 0.05% | Change From Baseline in Mean Non-Invasive Keratographic Tear Film Breakup Time (NIKBUT) of the Study Eye and Averaged for Both Eyes of a Participant at Week 12 | NIKBUTav for both eyes: Change at Week 12 | 0.04 seconds | Standard Deviation 5.117 |
Secondary
Change From Baseline in Mean OSDI Questionnaire Total Score and Individual Question Scores at Week 12
OSDI is a 12-item questionnaire developed to assess severity of DED. There are 3 question types: Have you experienced any of following (light sensitivity, eye feel gritty, sore eyes, blurred vision, and poor vision) during last week?(items 1-5); Have problems with your eyes limited you in performing any of following (reading, driving at night, working with computer, and watching TV) during last week? (items 6-9); and Have your eyes felt uncomfortable in any of following situations (windy, low humidity, air conditioned) during the last week? (items 10-12). Response of each of these questions were graded on a scale (that relate to the frequency of ocular surface disease effects) of 0 (none of the time) to 4 (all of the time).Total OSDI score was calculated using following formula: OSDI=(\[sum of scores for all questions answered\] × 100)/(\[total number of questions answered\] \* 4). Total OSDI score ranged from 0 to 100, with higher scores representing greater disability.
Time frame: Baseline, Week 12
Population: ITT population included all randomized participants. Here, 'Number analyzed' signifies participants evaluable for specified categories.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Lotemax Gel 0.5% and Restasis 0.05% | Change From Baseline in Mean OSDI Questionnaire Total Score and Individual Question Scores at Week 12 | Blurred vision: Baseline | 0.9 units on a scale | Standard Deviation 0.79 |
| Lotemax Gel 0.5% and Restasis 0.05% | Change From Baseline in Mean OSDI Questionnaire Total Score and Individual Question Scores at Week 12 | Light sensitivity: Change at Week 12 | -0.2 units on a scale | Standard Deviation 1.17 |
| Lotemax Gel 0.5% and Restasis 0.05% | Change From Baseline in Mean OSDI Questionnaire Total Score and Individual Question Scores at Week 12 | Gritty feel: Baseline | 1.5 units on a scale | Standard Deviation 0.97 |
| Lotemax Gel 0.5% and Restasis 0.05% | Change From Baseline in Mean OSDI Questionnaire Total Score and Individual Question Scores at Week 12 | Gritty feel: Change at Week 12 | -0.5 units on a scale | Standard Deviation 1.09 |
| Lotemax Gel 0.5% and Restasis 0.05% | Change From Baseline in Mean OSDI Questionnaire Total Score and Individual Question Scores at Week 12 | Painful or sore eyes: Baseline | 1.0 units on a scale | Standard Deviation 0.81 |
| Lotemax Gel 0.5% and Restasis 0.05% | Change From Baseline in Mean OSDI Questionnaire Total Score and Individual Question Scores at Week 12 | Painful or sore eyes: Change at Week 12 | -0.2 units on a scale | Standard Deviation 1.15 |
| Lotemax Gel 0.5% and Restasis 0.05% | Change From Baseline in Mean OSDI Questionnaire Total Score and Individual Question Scores at Week 12 | Light sensitivity: Baseline | 1.5 units on a scale | Standard Deviation 0.97 |
| Lotemax Gel 0.5% and Restasis 0.05% | Change From Baseline in Mean OSDI Questionnaire Total Score and Individual Question Scores at Week 12 | Blurred vision: Change at Week 12 | -0.2 units on a scale | Standard Deviation 0.88 |
| Lotemax Gel 0.5% and Restasis 0.05% | Change From Baseline in Mean OSDI Questionnaire Total Score and Individual Question Scores at Week 12 | Poor vision: Baseline | 0.8 units on a scale | Standard Deviation 0.77 |
| Lotemax Gel 0.5% and Restasis 0.05% | Change From Baseline in Mean OSDI Questionnaire Total Score and Individual Question Scores at Week 12 | Poor vision: Change at Week 12 | -0.1 units on a scale | Standard Deviation 0.94 |
| Lotemax Gel 0.5% and Restasis 0.05% | Change From Baseline in Mean OSDI Questionnaire Total Score and Individual Question Scores at Week 12 | Problem in reading: Baseline | 0.7 units on a scale | Standard Deviation 0.72 |
| Lotemax Gel 0.5% and Restasis 0.05% | Change From Baseline in Mean OSDI Questionnaire Total Score and Individual Question Scores at Week 12 | Problem in reading: Change at Week 12 | 0.0 units on a scale | Standard Deviation 0.68 |
| Lotemax Gel 0.5% and Restasis 0.05% | Change From Baseline in Mean OSDI Questionnaire Total Score and Individual Question Scores at Week 12 | Problem in driving at night: Baseline | 0.9 units on a scale | Standard Deviation 0.84 |
| Lotemax Gel 0.5% and Restasis 0.05% | Change From Baseline in Mean OSDI Questionnaire Total Score and Individual Question Scores at Week 12 | Problem in driving at night: Change at Week 12 | -0.2 units on a scale | Standard Deviation 1.11 |
| Lotemax Gel 0.5% and Restasis 0.05% | Change From Baseline in Mean OSDI Questionnaire Total Score and Individual Question Scores at Week 12 | Problem in working with computer: Baseline | 0.9 units on a scale | Standard Deviation 0.81 |
| Lotemax Gel 0.5% and Restasis 0.05% | Change From Baseline in Mean OSDI Questionnaire Total Score and Individual Question Scores at Week 12 | Problem in working with computer:Change at Week12 | -0.1 units on a scale | Standard Deviation 0.9 |
| Lotemax Gel 0.5% and Restasis 0.05% | Change From Baseline in Mean OSDI Questionnaire Total Score and Individual Question Scores at Week 12 | Problem in watching TV: Baseline | 0.9 units on a scale | Standard Deviation 0.6 |
| Lotemax Gel 0.5% and Restasis 0.05% | Change From Baseline in Mean OSDI Questionnaire Total Score and Individual Question Scores at Week 12 | Problem in watching TV: Change at Week 12 | -0.4 units on a scale | Standard Deviation 0.75 |
| Lotemax Gel 0.5% and Restasis 0.05% | Change From Baseline in Mean OSDI Questionnaire Total Score and Individual Question Scores at Week 12 | Uncomfortable in windy conditions: Baseline | 1.3 units on a scale | Standard Deviation 1.04 |
| Lotemax Gel 0.5% and Restasis 0.05% | Change From Baseline in Mean OSDI Questionnaire Total Score and Individual Question Scores at Week 12 | Uncomfortable in windy condition:Change at Week12 | -0.2 units on a scale | Standard Deviation 1.12 |
| Lotemax Gel 0.5% and Restasis 0.05% | Change From Baseline in Mean OSDI Questionnaire Total Score and Individual Question Scores at Week 12 | Uncomfortable in low humidity: Baseline | 1.5 units on a scale | Standard Deviation 1.12 |
| Lotemax Gel 0.5% and Restasis 0.05% | Change From Baseline in Mean OSDI Questionnaire Total Score and Individual Question Scores at Week 12 | Uncomfortable in low humidity: Change at Week 12 | -0.7 units on a scale | Standard Deviation 1.21 |
| Lotemax Gel 0.5% and Restasis 0.05% | Change From Baseline in Mean OSDI Questionnaire Total Score and Individual Question Scores at Week 12 | Uncomfortable in air conditioning: Baseline | 1.5 units on a scale | Standard Deviation 0.97 |
| Lotemax Gel 0.5% and Restasis 0.05% | Change From Baseline in Mean OSDI Questionnaire Total Score and Individual Question Scores at Week 12 | Uncomfortable in air conditioning:Change at Week12 | -0.3 units on a scale | Standard Deviation 1.11 |
| Lotemax Gel 0.5% and Restasis 0.05% | Change From Baseline in Mean OSDI Questionnaire Total Score and Individual Question Scores at Week 12 | Total OSDI score: Baseline | 27.9 units on a scale | Standard Deviation 8.41 |
| Lotemax Gel 0.5% and Restasis 0.05% | Change From Baseline in Mean OSDI Questionnaire Total Score and Individual Question Scores at Week 12 | Total OSDI score: Change at Week 12 | -5.6 units on a scale | Standard Deviation 14.5 |
| Lotemax Gel 0.5% | Change From Baseline in Mean OSDI Questionnaire Total Score and Individual Question Scores at Week 12 | Poor vision: Baseline | 0.7 units on a scale | Standard Deviation 0.79 |
| Lotemax Gel 0.5% | Change From Baseline in Mean OSDI Questionnaire Total Score and Individual Question Scores at Week 12 | Uncomfortable in low humidity: Baseline | 1.4 units on a scale | Standard Deviation 1.08 |
| Lotemax Gel 0.5% | Change From Baseline in Mean OSDI Questionnaire Total Score and Individual Question Scores at Week 12 | Poor vision: Change at Week 12 | 0.1 units on a scale | Standard Deviation 0.82 |
| Lotemax Gel 0.5% | Change From Baseline in Mean OSDI Questionnaire Total Score and Individual Question Scores at Week 12 | Problem in reading: Baseline | 0.8 units on a scale | Standard Deviation 0.75 |
| Lotemax Gel 0.5% | Change From Baseline in Mean OSDI Questionnaire Total Score and Individual Question Scores at Week 12 | Total OSDI score: Baseline | 27.8 units on a scale | Standard Deviation 9.18 |
| Lotemax Gel 0.5% | Change From Baseline in Mean OSDI Questionnaire Total Score and Individual Question Scores at Week 12 | Problem in reading: Change at Week 12 | 0.0 units on a scale | Standard Deviation 0.82 |
| Lotemax Gel 0.5% | Change From Baseline in Mean OSDI Questionnaire Total Score and Individual Question Scores at Week 12 | Uncomfortable in low humidity: Change at Week 12 | 0.2 units on a scale | Standard Deviation 1 |
| Lotemax Gel 0.5% | Change From Baseline in Mean OSDI Questionnaire Total Score and Individual Question Scores at Week 12 | Problem in driving at night: Baseline | 1.3 units on a scale | Standard Deviation 1.01 |
| Lotemax Gel 0.5% | Change From Baseline in Mean OSDI Questionnaire Total Score and Individual Question Scores at Week 12 | Problem in driving at night: Change at Week 12 | 0.0 units on a scale | Standard Deviation 1.22 |
| Lotemax Gel 0.5% | Change From Baseline in Mean OSDI Questionnaire Total Score and Individual Question Scores at Week 12 | Problem in working with computer: Baseline | 1.0 units on a scale | Standard Deviation 1.02 |
| Lotemax Gel 0.5% | Change From Baseline in Mean OSDI Questionnaire Total Score and Individual Question Scores at Week 12 | Uncomfortable in air conditioning: Baseline | 1.5 units on a scale | Standard Deviation 1.07 |
| Lotemax Gel 0.5% | Change From Baseline in Mean OSDI Questionnaire Total Score and Individual Question Scores at Week 12 | Problem in working with computer:Change at Week12 | -0.2 units on a scale | Standard Deviation 0.83 |
| Lotemax Gel 0.5% | Change From Baseline in Mean OSDI Questionnaire Total Score and Individual Question Scores at Week 12 | Problem in watching TV: Baseline | 1.0 units on a scale | Standard Deviation 0.94 |
| Lotemax Gel 0.5% | Change From Baseline in Mean OSDI Questionnaire Total Score and Individual Question Scores at Week 12 | Problem in watching TV: Change at Week 12 | -0.1 units on a scale | Standard Deviation 1.13 |
| Lotemax Gel 0.5% | Change From Baseline in Mean OSDI Questionnaire Total Score and Individual Question Scores at Week 12 | Light sensitivity: Baseline | 1.5 units on a scale | Standard Deviation 1.11 |
| Lotemax Gel 0.5% | Change From Baseline in Mean OSDI Questionnaire Total Score and Individual Question Scores at Week 12 | Light sensitivity: Change at Week 12 | -0.1 units on a scale | Standard Deviation 1.14 |
| Lotemax Gel 0.5% | Change From Baseline in Mean OSDI Questionnaire Total Score and Individual Question Scores at Week 12 | Uncomfortable in air conditioning:Change at Week12 | -0.3 units on a scale | Standard Deviation 1.43 |
| Lotemax Gel 0.5% | Change From Baseline in Mean OSDI Questionnaire Total Score and Individual Question Scores at Week 12 | Gritty feel: Baseline | 1.4 units on a scale | Standard Deviation 1.03 |
| Lotemax Gel 0.5% | Change From Baseline in Mean OSDI Questionnaire Total Score and Individual Question Scores at Week 12 | Uncomfortable in windy conditions: Baseline | 1.5 units on a scale | Standard Deviation 1.16 |
| Lotemax Gel 0.5% | Change From Baseline in Mean OSDI Questionnaire Total Score and Individual Question Scores at Week 12 | Gritty feel: Change at Week 12 | -0.4 units on a scale | Standard Deviation 1.14 |
| Lotemax Gel 0.5% | Change From Baseline in Mean OSDI Questionnaire Total Score and Individual Question Scores at Week 12 | Painful or sore eyes: Baseline | 0.8 units on a scale | Standard Deviation 0.77 |
| Lotemax Gel 0.5% | Change From Baseline in Mean OSDI Questionnaire Total Score and Individual Question Scores at Week 12 | Painful or sore eyes: Change at Week 12 | -0.3 units on a scale | Standard Deviation 0.83 |
| Lotemax Gel 0.5% | Change From Baseline in Mean OSDI Questionnaire Total Score and Individual Question Scores at Week 12 | Uncomfortable in windy condition:Change at Week12 | 0.0 units on a scale | Standard Deviation 1.18 |
| Lotemax Gel 0.5% | Change From Baseline in Mean OSDI Questionnaire Total Score and Individual Question Scores at Week 12 | Blurred vision: Baseline | 0.7 units on a scale | Standard Deviation 0.79 |
| Lotemax Gel 0.5% | Change From Baseline in Mean OSDI Questionnaire Total Score and Individual Question Scores at Week 12 | Blurred vision: Change at Week 12 | -0.1 units on a scale | Standard Deviation 0.91 |
| Lotemax Gel 0.5% | Change From Baseline in Mean OSDI Questionnaire Total Score and Individual Question Scores at Week 12 | Total OSDI score: Change at Week 12 | -3.2 units on a scale | Standard Deviation 15.05 |
| Restasis 0.05% | Change From Baseline in Mean OSDI Questionnaire Total Score and Individual Question Scores at Week 12 | Blurred vision: Baseline | 0.9 units on a scale | Standard Deviation 0.83 |
| Restasis 0.05% | Change From Baseline in Mean OSDI Questionnaire Total Score and Individual Question Scores at Week 12 | Painful or sore eyes: Baseline | 0.8 units on a scale | Standard Deviation 0.87 |
| Restasis 0.05% | Change From Baseline in Mean OSDI Questionnaire Total Score and Individual Question Scores at Week 12 | Light sensitivity: Baseline | 1.4 units on a scale | Standard Deviation 0.99 |
| Restasis 0.05% | Change From Baseline in Mean OSDI Questionnaire Total Score and Individual Question Scores at Week 12 | Poor vision: Change at Week 12 | 0.1 units on a scale | Standard Deviation 0.93 |
| Restasis 0.05% | Change From Baseline in Mean OSDI Questionnaire Total Score and Individual Question Scores at Week 12 | Uncomfortable in low humidity: Baseline | 1.3 units on a scale | Standard Deviation 0.88 |
| Restasis 0.05% | Change From Baseline in Mean OSDI Questionnaire Total Score and Individual Question Scores at Week 12 | Problem in watching TV: Change at Week 12 | 0.1 units on a scale | Standard Deviation 0.91 |
| Restasis 0.05% | Change From Baseline in Mean OSDI Questionnaire Total Score and Individual Question Scores at Week 12 | Problem in reading: Baseline | 0.9 units on a scale | Standard Deviation 0.77 |
| Restasis 0.05% | Change From Baseline in Mean OSDI Questionnaire Total Score and Individual Question Scores at Week 12 | Uncomfortable in air conditioning:Change at Week12 | -0.8 units on a scale | Standard Deviation 1.34 |
| Restasis 0.05% | Change From Baseline in Mean OSDI Questionnaire Total Score and Individual Question Scores at Week 12 | Light sensitivity: Change at Week 12 | -0.2 units on a scale | Standard Deviation 1.36 |
| Restasis 0.05% | Change From Baseline in Mean OSDI Questionnaire Total Score and Individual Question Scores at Week 12 | Problem in reading: Change at Week 12 | -0.2 units on a scale | Standard Deviation 1.07 |
| Restasis 0.05% | Change From Baseline in Mean OSDI Questionnaire Total Score and Individual Question Scores at Week 12 | Uncomfortable in windy condition:Change at Week12 | 0.0 units on a scale | Standard Deviation 1.33 |
| Restasis 0.05% | Change From Baseline in Mean OSDI Questionnaire Total Score and Individual Question Scores at Week 12 | Painful or sore eyes: Change at Week 12 | -0.2 units on a scale | Standard Deviation 0.71 |
| Restasis 0.05% | Change From Baseline in Mean OSDI Questionnaire Total Score and Individual Question Scores at Week 12 | Problem in driving at night: Baseline | 1.1 units on a scale | Standard Deviation 1.07 |
| Restasis 0.05% | Change From Baseline in Mean OSDI Questionnaire Total Score and Individual Question Scores at Week 12 | Uncomfortable in low humidity: Change at Week 12 | 0.0 units on a scale | Standard Deviation 1.32 |
| Restasis 0.05% | Change From Baseline in Mean OSDI Questionnaire Total Score and Individual Question Scores at Week 12 | Gritty feel: Baseline | 1.2 units on a scale | Standard Deviation 0.8 |
| Restasis 0.05% | Change From Baseline in Mean OSDI Questionnaire Total Score and Individual Question Scores at Week 12 | Problem in driving at night: Change at Week 12 | -0.2 units on a scale | Standard Deviation 1.05 |
| Restasis 0.05% | Change From Baseline in Mean OSDI Questionnaire Total Score and Individual Question Scores at Week 12 | Total OSDI score: Baseline | 26.5 units on a scale | Standard Deviation 8.12 |
| Restasis 0.05% | Change From Baseline in Mean OSDI Questionnaire Total Score and Individual Question Scores at Week 12 | Poor vision: Baseline | 0.5 units on a scale | Standard Deviation 0.71 |
| Restasis 0.05% | Change From Baseline in Mean OSDI Questionnaire Total Score and Individual Question Scores at Week 12 | Problem in working with computer: Baseline | 0.9 units on a scale | Standard Deviation 0.8 |
| Restasis 0.05% | Change From Baseline in Mean OSDI Questionnaire Total Score and Individual Question Scores at Week 12 | Blurred vision: Change at Week 12 | -0.1 units on a scale | Standard Deviation 0.89 |
| Restasis 0.05% | Change From Baseline in Mean OSDI Questionnaire Total Score and Individual Question Scores at Week 12 | Gritty feel: Change at Week 12 | -0.2 units on a scale | Standard Deviation 1.1 |
| Restasis 0.05% | Change From Baseline in Mean OSDI Questionnaire Total Score and Individual Question Scores at Week 12 | Problem in working with computer:Change at Week12 | -0.2 units on a scale | Standard Deviation 0.83 |
| Restasis 0.05% | Change From Baseline in Mean OSDI Questionnaire Total Score and Individual Question Scores at Week 12 | Uncomfortable in air conditioning: Baseline | 1.6 units on a scale | Standard Deviation 0.87 |
| Restasis 0.05% | Change From Baseline in Mean OSDI Questionnaire Total Score and Individual Question Scores at Week 12 | Uncomfortable in windy conditions: Baseline | 1.4 units on a scale | Standard Deviation 1 |
| Restasis 0.05% | Change From Baseline in Mean OSDI Questionnaire Total Score and Individual Question Scores at Week 12 | Problem in watching TV: Baseline | 0.8 units on a scale | Standard Deviation 0.78 |
| Restasis 0.05% | Change From Baseline in Mean OSDI Questionnaire Total Score and Individual Question Scores at Week 12 | Total OSDI score: Change at Week 12 | -4.0 units on a scale | Standard Deviation 15.14 |
Secondary
Change From Baseline in Mean Tear Film Breakup Time (TFBUT) (by Fluorescein Staining) of the Study Eye and Averaged for Both Eyes of a Participant at Week 12
The TFBUT was defined as the interval between the last complete blink and the first appearance of dark zones or spots, or disruption in the tear film. Tear film breakup time is a measure of the stability of the tear film protecting the cornea and bulbar conjunctiva. 5 microliters (μL) of fluorescein solution was instilled in the participant's eye, after which the participant blinked several times, then kept the eye open. The cornea was visualized through the slit lamp using appropriate barrier filters for the white light source. TFBUT was counted using a stopwatch. Three consecutive measurements were taken and averaged for actual TFBUT. TFBUT at Baseline (Day 0) was subtracted from TFBUT at Week 12 (Day 84) and reported as change. A higher number represented a lengthening in the TFBUT. A longer TFBUT indicated a more stable tear film.
Time frame: Baseline, Week 12
Population: ITT population included all randomized participants. Here, 'Number analyzed' signifies participants evaluable for specified categories.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Lotemax Gel 0.5% and Restasis 0.05% | Change From Baseline in Mean Tear Film Breakup Time (TFBUT) (by Fluorescein Staining) of the Study Eye and Averaged for Both Eyes of a Participant at Week 12 | Study eye: Baseline | 2.87 seconds | Standard Deviation 1.715 |
| Lotemax Gel 0.5% and Restasis 0.05% | Change From Baseline in Mean Tear Film Breakup Time (TFBUT) (by Fluorescein Staining) of the Study Eye and Averaged for Both Eyes of a Participant at Week 12 | Study eye: Change at Week 12 | 0.25 seconds | Standard Deviation 2.106 |
| Lotemax Gel 0.5% and Restasis 0.05% | Change From Baseline in Mean Tear Film Breakup Time (TFBUT) (by Fluorescein Staining) of the Study Eye and Averaged for Both Eyes of a Participant at Week 12 | Both eyes: Baseline | 3.01 seconds | Standard Deviation 2.042 |
| Lotemax Gel 0.5% and Restasis 0.05% | Change From Baseline in Mean Tear Film Breakup Time (TFBUT) (by Fluorescein Staining) of the Study Eye and Averaged for Both Eyes of a Participant at Week 12 | Both eyes: Change at Week 12 | 0.17 seconds | Standard Deviation 2.019 |
| Lotemax Gel 0.5% | Change From Baseline in Mean Tear Film Breakup Time (TFBUT) (by Fluorescein Staining) of the Study Eye and Averaged for Both Eyes of a Participant at Week 12 | Both eyes: Change at Week 12 | 0.57 seconds | Standard Deviation 2.305 |
| Lotemax Gel 0.5% | Change From Baseline in Mean Tear Film Breakup Time (TFBUT) (by Fluorescein Staining) of the Study Eye and Averaged for Both Eyes of a Participant at Week 12 | Study eye: Baseline | 3.23 seconds | Standard Deviation 1.739 |
| Lotemax Gel 0.5% | Change From Baseline in Mean Tear Film Breakup Time (TFBUT) (by Fluorescein Staining) of the Study Eye and Averaged for Both Eyes of a Participant at Week 12 | Both eyes: Baseline | 3.28 seconds | Standard Deviation 1.902 |
| Lotemax Gel 0.5% | Change From Baseline in Mean Tear Film Breakup Time (TFBUT) (by Fluorescein Staining) of the Study Eye and Averaged for Both Eyes of a Participant at Week 12 | Study eye: Change at Week 12 | 0.32 seconds | Standard Deviation 2.038 |
| Restasis 0.05% | Change From Baseline in Mean Tear Film Breakup Time (TFBUT) (by Fluorescein Staining) of the Study Eye and Averaged for Both Eyes of a Participant at Week 12 | Both eyes: Change at Week 12 | -0.17 seconds | Standard Deviation 2.286 |
| Restasis 0.05% | Change From Baseline in Mean Tear Film Breakup Time (TFBUT) (by Fluorescein Staining) of the Study Eye and Averaged for Both Eyes of a Participant at Week 12 | Study eye: Change at Week 12 | 0.16 seconds | Standard Deviation 1.807 |
| Restasis 0.05% | Change From Baseline in Mean Tear Film Breakup Time (TFBUT) (by Fluorescein Staining) of the Study Eye and Averaged for Both Eyes of a Participant at Week 12 | Both eyes: Baseline | 3.45 seconds | Standard Deviation 2.371 |
| Restasis 0.05% | Change From Baseline in Mean Tear Film Breakup Time (TFBUT) (by Fluorescein Staining) of the Study Eye and Averaged for Both Eyes of a Participant at Week 12 | Study eye: Baseline | 3.09 seconds | Standard Deviation 1.546 |
Secondary
Change From Baseline in Mean Tear Osmolarity Between Two Eyes of Participant at Week 12
Tear osmolarity was measured with the TearLab Osmolarity System. The TearLab instrument measures the impedance of 50 nL tear samples taken with a disposable lab-on-a-chip device. Tear samples from enrolled participants were taken at Weeks 2, 4, and 12 from each eye in duplicate with a tear sampler according to the manufacturer's instructions, and the tear osmolarity for each sample was read with the TearLab instrument. Osmolarity values were provided by the TearLab instrument in 3-digit units of mOsm. Change from mean baseline values for all participants within a treatment group was calculated for the difference between average values between 2 eyes at Week 12.
Time frame: Baseline, Week 12
Population: ITT population included all randomized participants. Here, 'Number analyzed' signifies participants evaluable at specified timepoints.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Lotemax Gel 0.5% and Restasis 0.05% | Change From Baseline in Mean Tear Osmolarity Between Two Eyes of Participant at Week 12 | Change at Week 12 | 0.6 mOsm | Standard Error 9.7 |
| Lotemax Gel 0.5% and Restasis 0.05% | Change From Baseline in Mean Tear Osmolarity Between Two Eyes of Participant at Week 12 | Baseline | 7.9 mOsm | Standard Error 5.72 |
| Lotemax Gel 0.5% | Change From Baseline in Mean Tear Osmolarity Between Two Eyes of Participant at Week 12 | Baseline | 5.4 mOsm | Standard Error 4.62 |
| Lotemax Gel 0.5% | Change From Baseline in Mean Tear Osmolarity Between Two Eyes of Participant at Week 12 | Change at Week 12 | 2.9 mOsm | Standard Error 6.62 |
| Restasis 0.05% | Change From Baseline in Mean Tear Osmolarity Between Two Eyes of Participant at Week 12 | Baseline | 7.2 mOsm | Standard Error 10.44 |
| Restasis 0.05% | Change From Baseline in Mean Tear Osmolarity Between Two Eyes of Participant at Week 12 | Change at Week 12 | -0.3 mOsm | Standard Error 11.52 |
Secondary
Change From Baseline in Mean Tear Osmolarity of Participant Worst Eye Value at Week 12
Tear osmolarity was measured with the TearLab Osmolarity System. The TearLab instrument measures the impedance of 50 nanoliters (nL) tear samples taken with a disposable lab-on-a-chip device. Tear samples from enrolled participants were taken at Weeks 2, 4, and 12 from each eye in duplicate with a tear sampler according to the manufacturer's instructions, and the tear osmolarity for each sample was read with the TearLab instrument. Osmolarity values were provided by the TearLab instrument in 3-digit units of milliosmoles (mOsm). Change from mean baseline values for all participants within a treatment group was calculated using a participant's worst eye value at Week 12.
Time frame: Baseline, Week 12
Population: ITT population included all randomized participants. Here, 'Number analyzed' signifies participants evaluable at specified timepoints.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Lotemax Gel 0.5% and Restasis 0.05% | Change From Baseline in Mean Tear Osmolarity of Participant Worst Eye Value at Week 12 | Baseline | 312.1 mOsm | Standard Deviation 11.48 |
| Lotemax Gel 0.5% and Restasis 0.05% | Change From Baseline in Mean Tear Osmolarity of Participant Worst Eye Value at Week 12 | Change at Week 12 | 0.7 mOsm | Standard Deviation 16.67 |
| Lotemax Gel 0.5% | Change From Baseline in Mean Tear Osmolarity of Participant Worst Eye Value at Week 12 | Baseline | 307.4 mOsm | Standard Deviation 8.91 |
| Lotemax Gel 0.5% | Change From Baseline in Mean Tear Osmolarity of Participant Worst Eye Value at Week 12 | Change at Week 12 | 4.3 mOsm | Standard Deviation 9.88 |
| Restasis 0.05% | Change From Baseline in Mean Tear Osmolarity of Participant Worst Eye Value at Week 12 | Baseline | 311.6 mOsm | Standard Deviation 17.11 |
| Restasis 0.05% | Change From Baseline in Mean Tear Osmolarity of Participant Worst Eye Value at Week 12 | Change at Week 12 | -1.5 mOsm | Standard Deviation 17.33 |
Secondary
Change From Baseline in Mean Total Combined Lissamine Green (LG) Staining (Nasal Plus Temporal Conjunctival) Score for the Study Eye and Averaged for Both Eyes at Week 12
LG staining is useful for monitoring evidence of eye dryness in conjunctival tissue. Scoring of conjunctival staining was done using Oxford conjunctival grading scale. The investigator instilled an ophthalmic dye (LG stain) on the eye and rated staining in 2 areas (nasal and temporal conjunctiva). Staining was rated on a 6-point scale from 0 (absent) to 5 (severe). The total score ranged from 0 (improvement; no conjunctival damage) to 12 (worsening; severe conjunctival damage).
Time frame: Baseline, Week 12
Population: ITT population included all randomized participants. Here, 'Number analyzed' signifies participants evaluable for specified categories.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Lotemax Gel 0.5% and Restasis 0.05% | Change From Baseline in Mean Total Combined Lissamine Green (LG) Staining (Nasal Plus Temporal Conjunctival) Score for the Study Eye and Averaged for Both Eyes at Week 12 | Score for study eye: Baseline | 8.5 units on a scale | Standard Deviation 5.1 |
| Lotemax Gel 0.5% and Restasis 0.05% | Change From Baseline in Mean Total Combined Lissamine Green (LG) Staining (Nasal Plus Temporal Conjunctival) Score for the Study Eye and Averaged for Both Eyes at Week 12 | Score for study eye: Change at Week 12 | -0.9 units on a scale | Standard Deviation 4.31 |
| Lotemax Gel 0.5% and Restasis 0.05% | Change From Baseline in Mean Total Combined Lissamine Green (LG) Staining (Nasal Plus Temporal Conjunctival) Score for the Study Eye and Averaged for Both Eyes at Week 12 | Score for both eyes: Baseline | 8.37 units on a scale | Standard Deviation 5.045 |
| Lotemax Gel 0.5% and Restasis 0.05% | Change From Baseline in Mean Total Combined Lissamine Green (LG) Staining (Nasal Plus Temporal Conjunctival) Score for the Study Eye and Averaged for Both Eyes at Week 12 | Score for both eyes: Change at Week 12 | -0.98 units on a scale | Standard Deviation 4.195 |
| Lotemax Gel 0.5% | Change From Baseline in Mean Total Combined Lissamine Green (LG) Staining (Nasal Plus Temporal Conjunctival) Score for the Study Eye and Averaged for Both Eyes at Week 12 | Score for both eyes: Change at Week 12 | -1.82 units on a scale | Standard Deviation 4.927 |
| Lotemax Gel 0.5% | Change From Baseline in Mean Total Combined Lissamine Green (LG) Staining (Nasal Plus Temporal Conjunctival) Score for the Study Eye and Averaged for Both Eyes at Week 12 | Score for study eye: Baseline | 9.2 units on a scale | Standard Deviation 4.68 |
| Lotemax Gel 0.5% | Change From Baseline in Mean Total Combined Lissamine Green (LG) Staining (Nasal Plus Temporal Conjunctival) Score for the Study Eye and Averaged for Both Eyes at Week 12 | Score for both eyes: Baseline | 9.06 units on a scale | Standard Deviation 4.107 |
| Lotemax Gel 0.5% | Change From Baseline in Mean Total Combined Lissamine Green (LG) Staining (Nasal Plus Temporal Conjunctival) Score for the Study Eye and Averaged for Both Eyes at Week 12 | Score for study eye: Change at Week 12 | -1.8 units on a scale | Standard Deviation 5.45 |
| Restasis 0.05% | Change From Baseline in Mean Total Combined Lissamine Green (LG) Staining (Nasal Plus Temporal Conjunctival) Score for the Study Eye and Averaged for Both Eyes at Week 12 | Score for both eyes: Change at Week 12 | -0.75 units on a scale | Standard Deviation 4.811 |
| Restasis 0.05% | Change From Baseline in Mean Total Combined Lissamine Green (LG) Staining (Nasal Plus Temporal Conjunctival) Score for the Study Eye and Averaged for Both Eyes at Week 12 | Score for study eye: Change at Week 12 | -1.2 units on a scale | Standard Deviation 4.32 |
| Restasis 0.05% | Change From Baseline in Mean Total Combined Lissamine Green (LG) Staining (Nasal Plus Temporal Conjunctival) Score for the Study Eye and Averaged for Both Eyes at Week 12 | Score for both eyes: Baseline | 7.35 units on a scale | Standard Deviation 4.542 |
| Restasis 0.05% | Change From Baseline in Mean Total Combined Lissamine Green (LG) Staining (Nasal Plus Temporal Conjunctival) Score for the Study Eye and Averaged for Both Eyes at Week 12 | Score for study eye: Baseline | 7.7 units on a scale | Standard Deviation 4.5 |
Secondary
Change From Baseline in Mean Value of Participant Worst Eye Score for Each Symptom (Including the Pre-Specified Worst Symptom) in the List of Possible Worst Symptoms at Week 12
Participants eligible for enrollment rated the severity of dry eye symptoms at Baseline (Day 0) on a 5-point grading scale (ranged from 0 \[no problem\] to 4 \[continuous or severe discomfort; intolerable\]) for each of 8 symptoms in the following symptom list prior to enrollment and then selected their most bothersome symptom: Photophobia, itchiness or scratchiness, grittiness or sandiness, foreign body sensation, haziness or blurriness, eye discomfort, burning or stinging, or photopsia (sensation of light or light flashes). Participants subsequently rated their dry eye symptom severity on the same 5-point grading scale at Week 2-Week 12 for study eye for the worst symptom identified at Baseline.
Time frame: Baseline, Week 12
Population: ITT population included all randomized participants. Here, 'Number analyzed' signifies participants evaluable for specified categories.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Lotemax Gel 0.5% and Restasis 0.05% | Change From Baseline in Mean Value of Participant Worst Eye Score for Each Symptom (Including the Pre-Specified Worst Symptom) in the List of Possible Worst Symptoms at Week 12 | Foreign body sensation: Baseline | 0.9 units on a scale | Standard Deviation 0.98 |
| Lotemax Gel 0.5% and Restasis 0.05% | Change From Baseline in Mean Value of Participant Worst Eye Score for Each Symptom (Including the Pre-Specified Worst Symptom) in the List of Possible Worst Symptoms at Week 12 | Burning or stinging: Change at Week 12 | -0.5 units on a scale | Standard Deviation 1.23 |
| Lotemax Gel 0.5% and Restasis 0.05% | Change From Baseline in Mean Value of Participant Worst Eye Score for Each Symptom (Including the Pre-Specified Worst Symptom) in the List of Possible Worst Symptoms at Week 12 | Eye discomfort: Baseline | 1.5 units on a scale | Standard Deviation 1.03 |
| Lotemax Gel 0.5% and Restasis 0.05% | Change From Baseline in Mean Value of Participant Worst Eye Score for Each Symptom (Including the Pre-Specified Worst Symptom) in the List of Possible Worst Symptoms at Week 12 | Eye discomfort: Change at Week 12 | -0.5 units on a scale | Standard Deviation 1.26 |
| Lotemax Gel 0.5% and Restasis 0.05% | Change From Baseline in Mean Value of Participant Worst Eye Score for Each Symptom (Including the Pre-Specified Worst Symptom) in the List of Possible Worst Symptoms at Week 12 | Burning or stinging: Baseline | 1.2 units on a scale | Standard Deviation 1.12 |
| Lotemax Gel 0.5% and Restasis 0.05% | Change From Baseline in Mean Value of Participant Worst Eye Score for Each Symptom (Including the Pre-Specified Worst Symptom) in the List of Possible Worst Symptoms at Week 12 | Foreign body sensation: Change at Week 12 | -0.3 units on a scale | Standard Deviation 1.4 |
| Lotemax Gel 0.5% and Restasis 0.05% | Change From Baseline in Mean Value of Participant Worst Eye Score for Each Symptom (Including the Pre-Specified Worst Symptom) in the List of Possible Worst Symptoms at Week 12 | Grittiness or sandiness: Baseline | 1.5 units on a scale | Standard Deviation 1.15 |
| Lotemax Gel 0.5% and Restasis 0.05% | Change From Baseline in Mean Value of Participant Worst Eye Score for Each Symptom (Including the Pre-Specified Worst Symptom) in the List of Possible Worst Symptoms at Week 12 | Grittiness or sandiness: Change at Week 12 | -0.5 units on a scale | Standard Deviation 1.18 |
| Lotemax Gel 0.5% and Restasis 0.05% | Change From Baseline in Mean Value of Participant Worst Eye Score for Each Symptom (Including the Pre-Specified Worst Symptom) in the List of Possible Worst Symptoms at Week 12 | Haziness or blurriness: Baseline | 1.2 units on a scale | Standard Deviation 0.87 |
| Lotemax Gel 0.5% and Restasis 0.05% | Change From Baseline in Mean Value of Participant Worst Eye Score for Each Symptom (Including the Pre-Specified Worst Symptom) in the List of Possible Worst Symptoms at Week 12 | Haziness or blurriness: Change at Week 12 | -0.4 units on a scale | Standard Deviation 0.88 |
| Lotemax Gel 0.5% and Restasis 0.05% | Change From Baseline in Mean Value of Participant Worst Eye Score for Each Symptom (Including the Pre-Specified Worst Symptom) in the List of Possible Worst Symptoms at Week 12 | Itchiness or scratchiness: Baseline | 1.4 units on a scale | Standard Deviation 0.99 |
| Lotemax Gel 0.5% and Restasis 0.05% | Change From Baseline in Mean Value of Participant Worst Eye Score for Each Symptom (Including the Pre-Specified Worst Symptom) in the List of Possible Worst Symptoms at Week 12 | Itchiness or scratchiness: Change at Week 12 | -0.4 units on a scale | Standard Deviation 1.28 |
| Lotemax Gel 0.5% and Restasis 0.05% | Change From Baseline in Mean Value of Participant Worst Eye Score for Each Symptom (Including the Pre-Specified Worst Symptom) in the List of Possible Worst Symptoms at Week 12 | Photophobia: Baseline | 1.3 units on a scale | Standard Deviation 1.21 |
| Lotemax Gel 0.5% and Restasis 0.05% | Change From Baseline in Mean Value of Participant Worst Eye Score for Each Symptom (Including the Pre-Specified Worst Symptom) in the List of Possible Worst Symptoms at Week 12 | Photophobia: Change at Week 12 | -0.2 units on a scale | Standard Deviation 1.05 |
| Lotemax Gel 0.5% and Restasis 0.05% | Change From Baseline in Mean Value of Participant Worst Eye Score for Each Symptom (Including the Pre-Specified Worst Symptom) in the List of Possible Worst Symptoms at Week 12 | Photopsia: Baseline | 0.2 units on a scale | Standard Deviation 0.46 |
| Lotemax Gel 0.5% and Restasis 0.05% | Change From Baseline in Mean Value of Participant Worst Eye Score for Each Symptom (Including the Pre-Specified Worst Symptom) in the List of Possible Worst Symptoms at Week 12 | Photopsia: Change at Week 12 | 0.0 units on a scale | Standard Deviation 0.66 |
| Lotemax Gel 0.5% and Restasis 0.05% | Change From Baseline in Mean Value of Participant Worst Eye Score for Each Symptom (Including the Pre-Specified Worst Symptom) in the List of Possible Worst Symptoms at Week 12 | Worst dry eye symptom: Baseline | 2.2 units on a scale | Standard Deviation 0.96 |
| Lotemax Gel 0.5% and Restasis 0.05% | Change From Baseline in Mean Value of Participant Worst Eye Score for Each Symptom (Including the Pre-Specified Worst Symptom) in the List of Possible Worst Symptoms at Week 12 | Worst dry eye symptom: Change at Week 12 | -0.8 units on a scale | Standard Deviation 1.34 |
| Lotemax Gel 0.5% | Change From Baseline in Mean Value of Participant Worst Eye Score for Each Symptom (Including the Pre-Specified Worst Symptom) in the List of Possible Worst Symptoms at Week 12 | Worst dry eye symptom: Change at Week 12 | -1.3 units on a scale | Standard Deviation 1.23 |
| Lotemax Gel 0.5% | Change From Baseline in Mean Value of Participant Worst Eye Score for Each Symptom (Including the Pre-Specified Worst Symptom) in the List of Possible Worst Symptoms at Week 12 | Burning or stinging: Baseline | 1.2 units on a scale | Standard Deviation 1.28 |
| Lotemax Gel 0.5% | Change From Baseline in Mean Value of Participant Worst Eye Score for Each Symptom (Including the Pre-Specified Worst Symptom) in the List of Possible Worst Symptoms at Week 12 | Haziness or blurriness: Change at Week 12 | -0.3 units on a scale | Standard Deviation 1.24 |
| Lotemax Gel 0.5% | Change From Baseline in Mean Value of Participant Worst Eye Score for Each Symptom (Including the Pre-Specified Worst Symptom) in the List of Possible Worst Symptoms at Week 12 | Photophobia: Baseline | 1.4 units on a scale | Standard Deviation 1.23 |
| Lotemax Gel 0.5% | Change From Baseline in Mean Value of Participant Worst Eye Score for Each Symptom (Including the Pre-Specified Worst Symptom) in the List of Possible Worst Symptoms at Week 12 | Burning or stinging: Change at Week 12 | -0.6 units on a scale | Standard Deviation 1.26 |
| Lotemax Gel 0.5% | Change From Baseline in Mean Value of Participant Worst Eye Score for Each Symptom (Including the Pre-Specified Worst Symptom) in the List of Possible Worst Symptoms at Week 12 | Photopsia: Baseline | 0.3 units on a scale | Standard Deviation 0.51 |
| Lotemax Gel 0.5% | Change From Baseline in Mean Value of Participant Worst Eye Score for Each Symptom (Including the Pre-Specified Worst Symptom) in the List of Possible Worst Symptoms at Week 12 | Photopsia: Change at Week 12 | -0.1 units on a scale | Standard Deviation 0.56 |
| Lotemax Gel 0.5% | Change From Baseline in Mean Value of Participant Worst Eye Score for Each Symptom (Including the Pre-Specified Worst Symptom) in the List of Possible Worst Symptoms at Week 12 | Eye discomfort: Baseline | 1.8 units on a scale | Standard Deviation 1.17 |
| Lotemax Gel 0.5% | Change From Baseline in Mean Value of Participant Worst Eye Score for Each Symptom (Including the Pre-Specified Worst Symptom) in the List of Possible Worst Symptoms at Week 12 | Itchiness or scratchiness: Baseline | 1.5 units on a scale | Standard Deviation 1.23 |
| Lotemax Gel 0.5% | Change From Baseline in Mean Value of Participant Worst Eye Score for Each Symptom (Including the Pre-Specified Worst Symptom) in the List of Possible Worst Symptoms at Week 12 | Worst dry eye symptom: Baseline | 2.6 units on a scale | Standard Deviation 0.94 |
| Lotemax Gel 0.5% | Change From Baseline in Mean Value of Participant Worst Eye Score for Each Symptom (Including the Pre-Specified Worst Symptom) in the List of Possible Worst Symptoms at Week 12 | Eye discomfort: Change at Week 12 | -0.9 units on a scale | Standard Deviation 1.06 |
| Lotemax Gel 0.5% | Change From Baseline in Mean Value of Participant Worst Eye Score for Each Symptom (Including the Pre-Specified Worst Symptom) in the List of Possible Worst Symptoms at Week 12 | Haziness or blurriness: Baseline | 1.2 units on a scale | Standard Deviation 1.12 |
| Lotemax Gel 0.5% | Change From Baseline in Mean Value of Participant Worst Eye Score for Each Symptom (Including the Pre-Specified Worst Symptom) in the List of Possible Worst Symptoms at Week 12 | Photophobia: Change at Week 12 | -0.2 units on a scale | Standard Deviation 1.21 |
| Lotemax Gel 0.5% | Change From Baseline in Mean Value of Participant Worst Eye Score for Each Symptom (Including the Pre-Specified Worst Symptom) in the List of Possible Worst Symptoms at Week 12 | Foreign body sensation: Baseline | 1.3 units on a scale | Standard Deviation 1.19 |
| Lotemax Gel 0.5% | Change From Baseline in Mean Value of Participant Worst Eye Score for Each Symptom (Including the Pre-Specified Worst Symptom) in the List of Possible Worst Symptoms at Week 12 | Grittiness or sandiness: Change at Week 12 | -0.8 units on a scale | Standard Deviation 1.1 |
| Lotemax Gel 0.5% | Change From Baseline in Mean Value of Participant Worst Eye Score for Each Symptom (Including the Pre-Specified Worst Symptom) in the List of Possible Worst Symptoms at Week 12 | Itchiness or scratchiness: Change at Week 12 | -0.6 units on a scale | Standard Deviation 1.17 |
| Lotemax Gel 0.5% | Change From Baseline in Mean Value of Participant Worst Eye Score for Each Symptom (Including the Pre-Specified Worst Symptom) in the List of Possible Worst Symptoms at Week 12 | Foreign body sensation: Change at Week 12 | -0.6 units on a scale | Standard Deviation 1.27 |
| Lotemax Gel 0.5% | Change From Baseline in Mean Value of Participant Worst Eye Score for Each Symptom (Including the Pre-Specified Worst Symptom) in the List of Possible Worst Symptoms at Week 12 | Grittiness or sandiness: Baseline | 1.6 units on a scale | Standard Deviation 1.16 |
| Restasis 0.05% | Change From Baseline in Mean Value of Participant Worst Eye Score for Each Symptom (Including the Pre-Specified Worst Symptom) in the List of Possible Worst Symptoms at Week 12 | Foreign body sensation: Change at Week 12 | -0.5 units on a scale | Standard Deviation 1.03 |
| Restasis 0.05% | Change From Baseline in Mean Value of Participant Worst Eye Score for Each Symptom (Including the Pre-Specified Worst Symptom) in the List of Possible Worst Symptoms at Week 12 | Grittiness or sandiness: Baseline | 1.3 units on a scale | Standard Deviation 1.05 |
| Restasis 0.05% | Change From Baseline in Mean Value of Participant Worst Eye Score for Each Symptom (Including the Pre-Specified Worst Symptom) in the List of Possible Worst Symptoms at Week 12 | Grittiness or sandiness: Change at Week 12 | -0.5 units on a scale | Standard Deviation 1.39 |
| Restasis 0.05% | Change From Baseline in Mean Value of Participant Worst Eye Score for Each Symptom (Including the Pre-Specified Worst Symptom) in the List of Possible Worst Symptoms at Week 12 | Photopsia: Baseline | 0.3 units on a scale | Standard Deviation 0.85 |
| Restasis 0.05% | Change From Baseline in Mean Value of Participant Worst Eye Score for Each Symptom (Including the Pre-Specified Worst Symptom) in the List of Possible Worst Symptoms at Week 12 | Haziness or blurriness: Baseline | 1.3 units on a scale | Standard Deviation 1.18 |
| Restasis 0.05% | Change From Baseline in Mean Value of Participant Worst Eye Score for Each Symptom (Including the Pre-Specified Worst Symptom) in the List of Possible Worst Symptoms at Week 12 | Worst dry eye symptom: Change at Week 12 | -1.5 units on a scale | Standard Deviation 1.12 |
| Restasis 0.05% | Change From Baseline in Mean Value of Participant Worst Eye Score for Each Symptom (Including the Pre-Specified Worst Symptom) in the List of Possible Worst Symptoms at Week 12 | Haziness or blurriness: Change at Week 12 | -0.6 units on a scale | Standard Deviation 1.03 |
| Restasis 0.05% | Change From Baseline in Mean Value of Participant Worst Eye Score for Each Symptom (Including the Pre-Specified Worst Symptom) in the List of Possible Worst Symptoms at Week 12 | Itchiness or scratchiness: Baseline | 1.5 units on a scale | Standard Deviation 0.97 |
| Restasis 0.05% | Change From Baseline in Mean Value of Participant Worst Eye Score for Each Symptom (Including the Pre-Specified Worst Symptom) in the List of Possible Worst Symptoms at Week 12 | Photopsia: Change at Week 12 | -0.1 units on a scale | Standard Deviation 1.1 |
| Restasis 0.05% | Change From Baseline in Mean Value of Participant Worst Eye Score for Each Symptom (Including the Pre-Specified Worst Symptom) in the List of Possible Worst Symptoms at Week 12 | Itchiness or scratchiness: Change at Week 12 | -0.5 units on a scale | Standard Deviation 1.12 |
| Restasis 0.05% | Change From Baseline in Mean Value of Participant Worst Eye Score for Each Symptom (Including the Pre-Specified Worst Symptom) in the List of Possible Worst Symptoms at Week 12 | Burning or stinging: Baseline | 1.0 units on a scale | Standard Deviation 1.24 |
| Restasis 0.05% | Change From Baseline in Mean Value of Participant Worst Eye Score for Each Symptom (Including the Pre-Specified Worst Symptom) in the List of Possible Worst Symptoms at Week 12 | Burning or stinging: Change at Week 12 | -0.3 units on a scale | Standard Deviation 1.35 |
| Restasis 0.05% | Change From Baseline in Mean Value of Participant Worst Eye Score for Each Symptom (Including the Pre-Specified Worst Symptom) in the List of Possible Worst Symptoms at Week 12 | Photophobia: Baseline | 1.5 units on a scale | Standard Deviation 1.09 |
| Restasis 0.05% | Change From Baseline in Mean Value of Participant Worst Eye Score for Each Symptom (Including the Pre-Specified Worst Symptom) in the List of Possible Worst Symptoms at Week 12 | Eye discomfort: Baseline | 1.8 units on a scale | Standard Deviation 1.06 |
| Restasis 0.05% | Change From Baseline in Mean Value of Participant Worst Eye Score for Each Symptom (Including the Pre-Specified Worst Symptom) in the List of Possible Worst Symptoms at Week 12 | Eye discomfort: Change at Week 12 | -1.1 units on a scale | Standard Deviation 0.97 |
| Restasis 0.05% | Change From Baseline in Mean Value of Participant Worst Eye Score for Each Symptom (Including the Pre-Specified Worst Symptom) in the List of Possible Worst Symptoms at Week 12 | Foreign body sensation: Baseline | 1.0 units on a scale | Standard Deviation 0.95 |
| Restasis 0.05% | Change From Baseline in Mean Value of Participant Worst Eye Score for Each Symptom (Including the Pre-Specified Worst Symptom) in the List of Possible Worst Symptoms at Week 12 | Photophobia: Change at Week 12 | -0.5 units on a scale | Standard Deviation 1.03 |
| Restasis 0.05% | Change From Baseline in Mean Value of Participant Worst Eye Score for Each Symptom (Including the Pre-Specified Worst Symptom) in the List of Possible Worst Symptoms at Week 12 | Worst dry eye symptom: Baseline | 2.5 units on a scale | Standard Deviation 0.94 |
Secondary
Change From Baseline in Non-Invasive Keratographic Limbal and Bulbar Ocular Redness Scores for Study Eye and Averaged for Both Eyes at Week 12, as Assessed by Investigator
The objective redness scoring assessment was conducted by automated means using an Oculus Keratograph 5M. Duplicate digital photographs of bulbar and limbal conjunctiva were taken with the Oculus Keratograph 5M instrument for each eye of a participant and the images were analyzed using R-Scan classification software to numerically rate the severity of ocular redness (bulbar and limbal redness) on a 4-point (0-3) grading scale, where score 0 = none absent; no redness present in the white of the eyes, 1 = mild, slightly dilated blood vessels seen in some portion of white of the eyes; color of vessels was typically pink, 2 = moderate more apparent dilation of blood vessels in the white of the eyes; vessel color was more intense (redder) and involves the majority of the vessel bed, 3 = severe numerous obvious dilated blood vessels throughout the white of the eyes; the vessel color was deep red. Keratograph 5M ocular redness grading results were averaged for each eye and for both eyes.
Time frame: Baseline, Week 12
Population: ITT population included all randomized participants. Here, 'Number analyzed' signifies participants evaluable for specified categories.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Lotemax Gel 0.5% and Restasis 0.05% | Change From Baseline in Non-Invasive Keratographic Limbal and Bulbar Ocular Redness Scores for Study Eye and Averaged for Both Eyes at Week 12, as Assessed by Investigator | Limbal study eye redness: Baseline | 0.608 units on a scale | Standard Deviation 0.1919 |
| Lotemax Gel 0.5% and Restasis 0.05% | Change From Baseline in Non-Invasive Keratographic Limbal and Bulbar Ocular Redness Scores for Study Eye and Averaged for Both Eyes at Week 12, as Assessed by Investigator | Limbal study eye redness: Change at Week 12 | 0.039 units on a scale | Standard Deviation 0.083 |
| Lotemax Gel 0.5% and Restasis 0.05% | Change From Baseline in Non-Invasive Keratographic Limbal and Bulbar Ocular Redness Scores for Study Eye and Averaged for Both Eyes at Week 12, as Assessed by Investigator | Limbal both eyes redness: Baseline | 0.643 units on a scale | Standard Deviation 0.2295 |
| Lotemax Gel 0.5% and Restasis 0.05% | Change From Baseline in Non-Invasive Keratographic Limbal and Bulbar Ocular Redness Scores for Study Eye and Averaged for Both Eyes at Week 12, as Assessed by Investigator | Limbal both eyes redness: Change at Week 12 | 0.038 units on a scale | Standard Deviation 0.1413 |
| Lotemax Gel 0.5% and Restasis 0.05% | Change From Baseline in Non-Invasive Keratographic Limbal and Bulbar Ocular Redness Scores for Study Eye and Averaged for Both Eyes at Week 12, as Assessed by Investigator | Bulbar study eye redness: Baseline | 0.975 units on a scale | Standard Deviation 0.3482 |
| Lotemax Gel 0.5% and Restasis 0.05% | Change From Baseline in Non-Invasive Keratographic Limbal and Bulbar Ocular Redness Scores for Study Eye and Averaged for Both Eyes at Week 12, as Assessed by Investigator | Bulbar study eye redness: Change at Week 12 | 0.139 units on a scale | Standard Deviation 0.2118 |
| Lotemax Gel 0.5% and Restasis 0.05% | Change From Baseline in Non-Invasive Keratographic Limbal and Bulbar Ocular Redness Scores for Study Eye and Averaged for Both Eyes at Week 12, as Assessed by Investigator | Bulbar both eyes redness: Baseline | 0.995 units on a scale | Standard Deviation 0.331 |
| Lotemax Gel 0.5% and Restasis 0.05% | Change From Baseline in Non-Invasive Keratographic Limbal and Bulbar Ocular Redness Scores for Study Eye and Averaged for Both Eyes at Week 12, as Assessed by Investigator | Bulbar both eyes redness: Change at Week 12 | 0.064 units on a scale | Standard Deviation 0.1949 |
| Lotemax Gel 0.5% | Change From Baseline in Non-Invasive Keratographic Limbal and Bulbar Ocular Redness Scores for Study Eye and Averaged for Both Eyes at Week 12, as Assessed by Investigator | Limbal both eyes redness: Baseline | 0.550 units on a scale | Standard Deviation 0.1915 |
| Lotemax Gel 0.5% | Change From Baseline in Non-Invasive Keratographic Limbal and Bulbar Ocular Redness Scores for Study Eye and Averaged for Both Eyes at Week 12, as Assessed by Investigator | Bulbar both eyes redness: Baseline | 0.992 units on a scale | Standard Deviation 0.212 |
| Lotemax Gel 0.5% | Change From Baseline in Non-Invasive Keratographic Limbal and Bulbar Ocular Redness Scores for Study Eye and Averaged for Both Eyes at Week 12, as Assessed by Investigator | Limbal both eyes redness: Change at Week 12 | 0.031 units on a scale | Standard Deviation 0.1473 |
| Lotemax Gel 0.5% | Change From Baseline in Non-Invasive Keratographic Limbal and Bulbar Ocular Redness Scores for Study Eye and Averaged for Both Eyes at Week 12, as Assessed by Investigator | Bulbar study eye redness: Baseline | 1.062 units on a scale | Standard Deviation 0.2807 |
| Lotemax Gel 0.5% | Change From Baseline in Non-Invasive Keratographic Limbal and Bulbar Ocular Redness Scores for Study Eye and Averaged for Both Eyes at Week 12, as Assessed by Investigator | Bulbar study eye redness: Change at Week 12 | -0.069 units on a scale | Standard Deviation 0.3146 |
| Lotemax Gel 0.5% | Change From Baseline in Non-Invasive Keratographic Limbal and Bulbar Ocular Redness Scores for Study Eye and Averaged for Both Eyes at Week 12, as Assessed by Investigator | Limbal study eye redness: Baseline | 0.615 units on a scale | Standard Deviation 0.2379 |
| Lotemax Gel 0.5% | Change From Baseline in Non-Invasive Keratographic Limbal and Bulbar Ocular Redness Scores for Study Eye and Averaged for Both Eyes at Week 12, as Assessed by Investigator | Limbal study eye redness: Change at Week 12 | 0.015 units on a scale | Standard Deviation 0.176 |
| Lotemax Gel 0.5% | Change From Baseline in Non-Invasive Keratographic Limbal and Bulbar Ocular Redness Scores for Study Eye and Averaged for Both Eyes at Week 12, as Assessed by Investigator | Bulbar both eyes redness: Change at Week 12 | -0.038 units on a scale | Standard Deviation 0.2444 |
| Restasis 0.05% | Change From Baseline in Non-Invasive Keratographic Limbal and Bulbar Ocular Redness Scores for Study Eye and Averaged for Both Eyes at Week 12, as Assessed by Investigator | Limbal both eyes redness: Baseline | 0.734 units on a scale | Standard Deviation 0.3225 |
| Restasis 0.05% | Change From Baseline in Non-Invasive Keratographic Limbal and Bulbar Ocular Redness Scores for Study Eye and Averaged for Both Eyes at Week 12, as Assessed by Investigator | Limbal study eye redness: Change at Week 12 | 0.004 units on a scale | Standard Deviation 0.2171 |
| Restasis 0.05% | Change From Baseline in Non-Invasive Keratographic Limbal and Bulbar Ocular Redness Scores for Study Eye and Averaged for Both Eyes at Week 12, as Assessed by Investigator | Limbal study eye redness: Baseline | 0.625 units on a scale | Standard Deviation 0.3917 |
| Restasis 0.05% | Change From Baseline in Non-Invasive Keratographic Limbal and Bulbar Ocular Redness Scores for Study Eye and Averaged for Both Eyes at Week 12, as Assessed by Investigator | Limbal both eyes redness: Change at Week 12 | -0.050 units on a scale | Standard Deviation 0.134 |
| Restasis 0.05% | Change From Baseline in Non-Invasive Keratographic Limbal and Bulbar Ocular Redness Scores for Study Eye and Averaged for Both Eyes at Week 12, as Assessed by Investigator | Bulbar both eyes redness: Baseline | 0.994 units on a scale | Standard Deviation 0.2354 |
| Restasis 0.05% | Change From Baseline in Non-Invasive Keratographic Limbal and Bulbar Ocular Redness Scores for Study Eye and Averaged for Both Eyes at Week 12, as Assessed by Investigator | Bulbar study eye redness: Change at Week 12 | -0.050 units on a scale | Standard Deviation 0.3162 |
| Restasis 0.05% | Change From Baseline in Non-Invasive Keratographic Limbal and Bulbar Ocular Redness Scores for Study Eye and Averaged for Both Eyes at Week 12, as Assessed by Investigator | Bulbar study eye redness: Baseline | 0.965 units on a scale | Standard Deviation 0.3132 |
| Restasis 0.05% | Change From Baseline in Non-Invasive Keratographic Limbal and Bulbar Ocular Redness Scores for Study Eye and Averaged for Both Eyes at Week 12, as Assessed by Investigator | Bulbar both eyes redness: Change at Week 12 | -0.089 units on a scale | Standard Deviation 0.1939 |
Secondary
Change From Baseline in Ocular Redness Score for Study Eye and Averaged for Both Eyes at Week 12, as Assessed by Investigator
The Investigator subjectively rated the degree of eye redness on a 4-point (0-3) grading scale prior to any objective grading of eye redness for a participant, where score 0 = none absent; no redness present in the white of the eyes, 1 = mild, slightly dilated blood vessels seen in some portion of the white of the eyes; the color of vessels was typically pink, 2 = moderate more apparent dilation of blood vessels in the white of the eyes; vessel color was more intense (redder) and involves the majority of the vessel bed, 3 = severe numerous obvious dilated blood vessels throughout the white of the eyes; the vessel color was deep red.
Time frame: Baseline, Week 12
Population: ITT population included all randomized participants. Here, 'Number analyzed' signifies participants evaluable for specified categories.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Lotemax Gel 0.5% and Restasis 0.05% | Change From Baseline in Ocular Redness Score for Study Eye and Averaged for Both Eyes at Week 12, as Assessed by Investigator | Redness of study eye: Baseline | 1.0 units on a scale | Standard Deviation 0.79 |
| Lotemax Gel 0.5% and Restasis 0.05% | Change From Baseline in Ocular Redness Score for Study Eye and Averaged for Both Eyes at Week 12, as Assessed by Investigator | Redness of study eye: Change at Week 12 | -0.1 units on a scale | Standard Deviation 0.6 |
| Lotemax Gel 0.5% and Restasis 0.05% | Change From Baseline in Ocular Redness Score for Study Eye and Averaged for Both Eyes at Week 12, as Assessed by Investigator | Redness of both eyes: Baseline | 1.00 units on a scale | Standard Deviation 0.76 |
| Lotemax Gel 0.5% and Restasis 0.05% | Change From Baseline in Ocular Redness Score for Study Eye and Averaged for Both Eyes at Week 12, as Assessed by Investigator | Redness of both eyes: Change at Week 12 | -0.10 units on a scale | Standard Deviation 0.583 |
| Lotemax Gel 0.5% | Change From Baseline in Ocular Redness Score for Study Eye and Averaged for Both Eyes at Week 12, as Assessed by Investigator | Redness of both eyes: Change at Week 12 | -0.21 units on a scale | Standard Deviation 0.698 |
| Lotemax Gel 0.5% | Change From Baseline in Ocular Redness Score for Study Eye and Averaged for Both Eyes at Week 12, as Assessed by Investigator | Redness of study eye: Baseline | 1.0 units on a scale | Standard Deviation 0.7 |
| Lotemax Gel 0.5% | Change From Baseline in Ocular Redness Score for Study Eye and Averaged for Both Eyes at Week 12, as Assessed by Investigator | Redness of both eyes: Baseline | 0.97 units on a scale | Standard Deviation 0.696 |
| Lotemax Gel 0.5% | Change From Baseline in Ocular Redness Score for Study Eye and Averaged for Both Eyes at Week 12, as Assessed by Investigator | Redness of study eye: Change at Week 12 | -0.2 units on a scale | Standard Deviation 0.69 |
| Restasis 0.05% | Change From Baseline in Ocular Redness Score for Study Eye and Averaged for Both Eyes at Week 12, as Assessed by Investigator | Redness of both eyes: Change at Week 12 | -0.12 units on a scale | Standard Deviation 0.625 |
| Restasis 0.05% | Change From Baseline in Ocular Redness Score for Study Eye and Averaged for Both Eyes at Week 12, as Assessed by Investigator | Redness of study eye: Change at Week 12 | -0.1 units on a scale | Standard Deviation 0.66 |
| Restasis 0.05% | Change From Baseline in Ocular Redness Score for Study Eye and Averaged for Both Eyes at Week 12, as Assessed by Investigator | Redness of both eyes: Baseline | 1.06 units on a scale | Standard Deviation 0.726 |
| Restasis 0.05% | Change From Baseline in Ocular Redness Score for Study Eye and Averaged for Both Eyes at Week 12, as Assessed by Investigator | Redness of study eye: Baseline | 1.0 units on a scale | Standard Deviation 0.68 |
Secondary
Number of Participants With Overall Change From Baseline in Dry Symptoms at Week 12 as Assessed Independently by Investigators and Participants
Participants and investigators independently rated the overall change from baseline in dry eye conditions for each participant on a 7-point Likert scale at Week 12. The scale ranged from +3 to -3, where +3 = Substantial improvement in dry eye; little or no awareness of dry eye, +2 = Some improvement in dry eye, +1 = Little improvement in dry eye, 0 = No improvement in dry eye, -1 = Slight worsening of dry eye, -2 = Some worsening of dry eye, and -3 = Substantial worsening of dry eye.
Time frame: Baseline, Week 12
Population: ITT population included all randomized participants. Here, 'Overall number of participants analyzed' signifies participants evaluable for specified categories; that is, participants who had investigator global improvement assessment or participant-reported global improvement assessments.
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| Lotemax Gel 0.5% and Restasis 0.05% | Number of Participants With Overall Change From Baseline in Dry Symptoms at Week 12 as Assessed Independently by Investigators and Participants | Participant-reported: | 0 | 6 Participants |
| Lotemax Gel 0.5% and Restasis 0.05% | Number of Participants With Overall Change From Baseline in Dry Symptoms at Week 12 as Assessed Independently by Investigators and Participants | Investigator-reported: | -2 | 1 Participants |
| Lotemax Gel 0.5% and Restasis 0.05% | Number of Participants With Overall Change From Baseline in Dry Symptoms at Week 12 as Assessed Independently by Investigators and Participants | Participant-reported: | -2 | 0 Participants |
| Lotemax Gel 0.5% and Restasis 0.05% | Number of Participants With Overall Change From Baseline in Dry Symptoms at Week 12 as Assessed Independently by Investigators and Participants | Participant-reported: | +1 | 8 Participants |
| Lotemax Gel 0.5% and Restasis 0.05% | Number of Participants With Overall Change From Baseline in Dry Symptoms at Week 12 as Assessed Independently by Investigators and Participants | Investigator-reported: | -3 | 0 Participants |
| Lotemax Gel 0.5% and Restasis 0.05% | Number of Participants With Overall Change From Baseline in Dry Symptoms at Week 12 as Assessed Independently by Investigators and Participants | Participant-reported: | -3 | 1 Participants |
| Lotemax Gel 0.5% and Restasis 0.05% | Number of Participants With Overall Change From Baseline in Dry Symptoms at Week 12 as Assessed Independently by Investigators and Participants | Participant-reported: | +2 | 10 Participants |
| Lotemax Gel 0.5% and Restasis 0.05% | Number of Participants With Overall Change From Baseline in Dry Symptoms at Week 12 as Assessed Independently by Investigators and Participants | Participant-reported: | +3 | 4 Participants |
| Lotemax Gel 0.5% and Restasis 0.05% | Number of Participants With Overall Change From Baseline in Dry Symptoms at Week 12 as Assessed Independently by Investigators and Participants | Participant-reported: | -1 | 2 Participants |
| Lotemax Gel 0.5% and Restasis 0.05% | Number of Participants With Overall Change From Baseline in Dry Symptoms at Week 12 as Assessed Independently by Investigators and Participants | Investigator-reported: | 0 | 5 Participants |
| Lotemax Gel 0.5% and Restasis 0.05% | Number of Participants With Overall Change From Baseline in Dry Symptoms at Week 12 as Assessed Independently by Investigators and Participants | Investigator-reported: | +2 | 7 Participants |
| Lotemax Gel 0.5% and Restasis 0.05% | Number of Participants With Overall Change From Baseline in Dry Symptoms at Week 12 as Assessed Independently by Investigators and Participants | Investigator-reported: | +1 | 16 Participants |
| Lotemax Gel 0.5% and Restasis 0.05% | Number of Participants With Overall Change From Baseline in Dry Symptoms at Week 12 as Assessed Independently by Investigators and Participants | Investigator-reported: | -1 | 2 Participants |
| Lotemax Gel 0.5% and Restasis 0.05% | Number of Participants With Overall Change From Baseline in Dry Symptoms at Week 12 as Assessed Independently by Investigators and Participants | Investigator-reported: | +3 | 0 Participants |
| Lotemax Gel 0.5% | Number of Participants With Overall Change From Baseline in Dry Symptoms at Week 12 as Assessed Independently by Investigators and Participants | Participant-reported: | 0 | 5 Participants |
| Lotemax Gel 0.5% | Number of Participants With Overall Change From Baseline in Dry Symptoms at Week 12 as Assessed Independently by Investigators and Participants | Investigator-reported: | +3 | 2 Participants |
| Lotemax Gel 0.5% | Number of Participants With Overall Change From Baseline in Dry Symptoms at Week 12 as Assessed Independently by Investigators and Participants | Investigator-reported: | +2 | 11 Participants |
| Lotemax Gel 0.5% | Number of Participants With Overall Change From Baseline in Dry Symptoms at Week 12 as Assessed Independently by Investigators and Participants | Investigator-reported: | +1 | 12 Participants |
| Lotemax Gel 0.5% | Number of Participants With Overall Change From Baseline in Dry Symptoms at Week 12 as Assessed Independently by Investigators and Participants | Investigator-reported: | 0 | 8 Participants |
| Lotemax Gel 0.5% | Number of Participants With Overall Change From Baseline in Dry Symptoms at Week 12 as Assessed Independently by Investigators and Participants | Investigator-reported: | -1 | 1 Participants |
| Lotemax Gel 0.5% | Number of Participants With Overall Change From Baseline in Dry Symptoms at Week 12 as Assessed Independently by Investigators and Participants | Investigator-reported: | -2 | 0 Participants |
| Lotemax Gel 0.5% | Number of Participants With Overall Change From Baseline in Dry Symptoms at Week 12 as Assessed Independently by Investigators and Participants | Investigator-reported: | -3 | 0 Participants |
| Lotemax Gel 0.5% | Number of Participants With Overall Change From Baseline in Dry Symptoms at Week 12 as Assessed Independently by Investigators and Participants | Participant-reported: | +3 | 6 Participants |
| Lotemax Gel 0.5% | Number of Participants With Overall Change From Baseline in Dry Symptoms at Week 12 as Assessed Independently by Investigators and Participants | Participant-reported: | +2 | 15 Participants |
| Lotemax Gel 0.5% | Number of Participants With Overall Change From Baseline in Dry Symptoms at Week 12 as Assessed Independently by Investigators and Participants | Participant-reported: | +1 | 7 Participants |
| Lotemax Gel 0.5% | Number of Participants With Overall Change From Baseline in Dry Symptoms at Week 12 as Assessed Independently by Investigators and Participants | Participant-reported: | -1 | 1 Participants |
| Lotemax Gel 0.5% | Number of Participants With Overall Change From Baseline in Dry Symptoms at Week 12 as Assessed Independently by Investigators and Participants | Participant-reported: | -2 | 0 Participants |
| Lotemax Gel 0.5% | Number of Participants With Overall Change From Baseline in Dry Symptoms at Week 12 as Assessed Independently by Investigators and Participants | Participant-reported: | -3 | 0 Participants |
| Restasis 0.05% | Number of Participants With Overall Change From Baseline in Dry Symptoms at Week 12 as Assessed Independently by Investigators and Participants | Participant-reported: | -2 | 0 Participants |
| Restasis 0.05% | Number of Participants With Overall Change From Baseline in Dry Symptoms at Week 12 as Assessed Independently by Investigators and Participants | Participant-reported: | +1 | 7 Participants |
| Restasis 0.05% | Number of Participants With Overall Change From Baseline in Dry Symptoms at Week 12 as Assessed Independently by Investigators and Participants | Investigator-reported: | -1 | 1 Participants |
| Restasis 0.05% | Number of Participants With Overall Change From Baseline in Dry Symptoms at Week 12 as Assessed Independently by Investigators and Participants | Investigator-reported: | 0 | 4 Participants |
| Restasis 0.05% | Number of Participants With Overall Change From Baseline in Dry Symptoms at Week 12 as Assessed Independently by Investigators and Participants | Participant-reported: | 0 | 2 Participants |
| Restasis 0.05% | Number of Participants With Overall Change From Baseline in Dry Symptoms at Week 12 as Assessed Independently by Investigators and Participants | Investigator-reported: | +1 | 14 Participants |
| Restasis 0.05% | Number of Participants With Overall Change From Baseline in Dry Symptoms at Week 12 as Assessed Independently by Investigators and Participants | Investigator-reported: | +3 | 3 Participants |
| Restasis 0.05% | Number of Participants With Overall Change From Baseline in Dry Symptoms at Week 12 as Assessed Independently by Investigators and Participants | Participant-reported: | -1 | 1 Participants |
| Restasis 0.05% | Number of Participants With Overall Change From Baseline in Dry Symptoms at Week 12 as Assessed Independently by Investigators and Participants | Investigator-reported: | +2 | 10 Participants |
| Restasis 0.05% | Number of Participants With Overall Change From Baseline in Dry Symptoms at Week 12 as Assessed Independently by Investigators and Participants | Participant-reported: | +3 | 9 Participants |
| Restasis 0.05% | Number of Participants With Overall Change From Baseline in Dry Symptoms at Week 12 as Assessed Independently by Investigators and Participants | Investigator-reported: | -3 | 0 Participants |
| Restasis 0.05% | Number of Participants With Overall Change From Baseline in Dry Symptoms at Week 12 as Assessed Independently by Investigators and Participants | Participant-reported: | -3 | 0 Participants |
| Restasis 0.05% | Number of Participants With Overall Change From Baseline in Dry Symptoms at Week 12 as Assessed Independently by Investigators and Participants | Participant-reported: | +2 | 14 Participants |
| Restasis 0.05% | Number of Participants With Overall Change From Baseline in Dry Symptoms at Week 12 as Assessed Independently by Investigators and Participants | Investigator-reported: | -2 | 1 Participants |